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ABSTRACT 
More than one-third of all Magnetic Resonance Imaging (MRI) scans employ image-
enhancing contrast agents to increase the differential signal intensity between diseased and normal 
tissue. Because current clinical contrast agents exhibit low relaxivity (mM-1 s-1), low dose 
efficiency, and rapid secretion, we have designed a group of protein-based MRI contrast agents 
with multiple gadolinium binding sites. In this study, the developed purification method for Class 
ProCA-3 agents allows for a quick and cost-effective way to abstract up to 109 mg of pure, soluble 
protein from a 1L E. Coli cell pellet devoid of DNA or RNA “contamination” for extensive animal 
studies. Circular dichroism far-UV spectra ensure the metal stability of the agents, revealing 
maintenance of their native α-helical structure in the presence and absence of metal ions. 
Furthermore, substantial evidence supports the high dose efficiency of these agents, exhibiting up  
 
to five folds higher relaxivity than their analogous commercial competitors.  
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1. INTRODUCTION 
1.1. Modern Methods for Medical Imaging 
1.1.1. Background 
Medical imaging is a clinical discipline referring to the techniques and processes used to 
create in vivo images of the human body for clinical applications or medicinal science [1]. In its 
broadest sense, the incorporation of radiology, medical photography, nuclear medicine, 
investigative radiological sciences, endoscopy, thermography and microscopy allows this 
division of the medical field to improve diagnoses and medical care for patients [1-2]. When 
applied effectively, medical imaging enables less-invasive prognosis and diagnosis, detects 
disease at its earliest and most curable stage, and allows for decreased post-treatment disability, 
leading to greater patient comfort and improved treatment selection. Thus, this standard of 
modern medical care not only “continues to empower doctors and medical professionals to view 
the human body and its organ systems with ever increasing clarity and accuracy” but as a result, 
has the potential to drastically reduce the cost of healthcare by shortening hospital stays due to 
faster recovery times. This is evidenced by fewer pre- and post-operative complications [2]. 
Therefore, the clinical and medicinal scientific communities are actively developing a number of 
different imaging techniques, striving to improve their role in disease prognosis, diagnosis, and 
treatment (Figure 1.1). 
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Figure 1.1. Summary of current clinically applied imaging techniques for disease diagnosis. 
 
 The availability of a wide variety of imaging techniques allows the physician and 
relevant medical staff to optimize patient treatment outcomes. In most cases, one or more of the 
techniques are combined with another to effectively diagnose and treat a patient [2].  
Although medical imaging technologies provide a wide range of clinical and patient 
benefits, many of the techniques use X-ray radiation (X-rays and CT scans), posing dose-
dependent risks to patients. The “approach taken by the FDA is that the slight risk from radiation 
is outweighed by the medical benefit of medically necessary CT scans and X-rays [2].” Still, 
3 
 
there are alternative imaging techniques that function without the use of radiation and allow for 
excellent resolution between diseased and normal tissue. For example, like Computed 
Tomography (CT), MRI also has the ability to create a two- and three-dimensional image of a 
thin slice of the body. However, unlike CT, MRI does not involve the use of ionizing radiation 
and is therefore not associated with the same health hazards such as the possibility of inducing 
cancer due to absorbed X-rays. Additionally, in contrast to X-ray and CT methodologies, there 
are no limitations to the number of MRI scans a patient can receive [1]. Although MRI can 
provide high-resolution images via optimized instrumental parameters and pulse sequences, it 
has a low sensitivity and achieves better images with supplementation of a contrast agent that 
increases the signal to noise ratio detected by changes in water relaxivity. Thus, the development 
of MRI contrast enhancing agents proves as an excellent technique to further improve medical 
imaging and thus medical diagnoses and treatment [3].  
1.1.2. Principles of MRI and the Use of Contrast Agents 
MRI is a non-invasive nuclear magnetic resonance (NMR) imaging technique that exploits 
the magnetic properties of hydrogen and its interaction with both a large external magnetic field 
and radiowaves to produce high resolution three-dimensional images of the body for disease 
diagnosis [4]. Although biological tissues are predominantly 12C, 16O, 1H, and 14N, hydrogen is 
the most abundant [5]. The majority of hydrogen protons observed in clinical imaging are of 
water molecules because they “have a significant magnetic moment and are nearly 70% 
abundant in the human body” [4-5]. As will be later explained, the varying molecular structures 
and the amount of hydrogen in various tissues affect how the protons behave in an external 
magnetic field and thus allow for potential delineation between different tissues. 
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The principles detailing the mechanism behind MRI signals are complex. From a simplified 
“classical” view, the nucleus of an atom is composed of subatomic particles protons and neutrons 
that spin about their axis [4]. More relevant to MRI signals, each nuclei of the hydrogen atoms in 
solution contain a single proton spinning about its axis, producing an angular momentum (J) and 
a magnetic moment (µ) (Figure 1.2) [4].  
 
Figure 1.2. Simplified schematic illustration of the intrinsic properties of the hydrogen proton in 
its original state. (A) Hydrogen proton spinning about its axis. (B) Generated angular momentum 
from the proton spin. 
 
The following equations are descriptive of the angular momentum and the magnetic moment: 
 J =  mω = mvr         (Equation 1.1) 
where m is the mass of the proton, v is the velocity of the proton, and r is the radius or distance 
of the proton from the fulcrum [5], and 
µ = τmax / B          (Equation 1.2) 
where τmax is the maximum torque generated and B is the magnetic field generated by the 
movement of the proton [5]. 
The angular momentum and magnetic property of the nuclei mentioned above stems from the 
mass and positive charge of the proton. Nuclei containing an even number of protons and 
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neutrons possess a net angular momentum of zero while those with an odd mass or odd atomic 
number (protons) possess a certain angular momentum and have net spins of one of two possible 
orientations characterized by magnetic quantum number of ± 1/2. For the purposes of MRI and 
NMR, atoms with paired spins tend to cancel so atoms containing an odd number of protons (like 
hydrogen) or neutrons are ideal for observing changes in the local magnetic field [5]. These net 
spins generate small magnetic fields due to their vibrational and rotational motions, giving rise to 
the magnetic moment. The ratio between the angular momentum and magnetic moment of the 
nuclei gives rise the gyromagnetic ratio (γ), a constant specific to each magnetically active nuclei 
(Equation 1.3) [5]. The gyromagnetic ratio of hydrogen is 42.6 MHz/Tesla [6].  
                                      µ = γ J    (Equation 1.3) 
In the absence of an external magnetic field, these charged nuclei are in a lower energy 
level and have randomly oriented spins of equal energy. When an external magnetic field (B0) is 
applied, the axis of rotation of the nuclei will precess around that of the applied magnetic field. 
The frequency of precession is termed Larmor frequency, a parameter that must be optimized for 
efficient relaxation of a contrast agent [7]. Subsequently, in this excited state, the spins of the 
nuclei will align parallel or antiparallel (with or opposed) to the magnetic field. Combined with 
the magnetic and electromagnetic fields, MRI uses non-ionizing radiation radiowaves in the 
form of a radiofrequency pulse (RF) to manipulate the magnetization of protons and perturb their 
alignment to the external magnetic field. As the radiofrequency pulse is removed, the spins of the 
nuclei decay from the higher energy state to their lower energy state through a process termed 
relaxation. It’s important to note that there are radiofrequency pulse sequences designed to 
highlight T1 and T2 changes, two distinct relaxation processes [8]. The change in “distribution 
of the magnetic moments of the protons from random to directed and their return to normal” via 
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relaxation constitutes the MRI signal [8]. The basic principles of MRI are summarized in Figure 
1.3. 
 
Figure 1.3. Simplification of the basic principles underlying MRI.   
 
There are two dominant relaxation processes: spin-lattice (longitudinal) relaxation and 
spin-spin (transverse) relaxation [9]. The nuclei spins aligned parallel or perpendicular to the 
external magnetic field are generally dominated by spin-lattice relaxation time T1. The lattice is 
descriptive of the sample in which the nuclei are held. The lattice field results from the magnetic 
field caused by the vibrational and rotational frequencies of the nuclei [9]. Components of the 
lattice field can interact with high energy state nuclei and cause them to lose energy, relaxing 
them back to their lower energy state. The average time -it takes for the higher energy state 
nuclei to relax to a lower energy state with respect to the lattice field is termed longitudinal 
relaxation time T1 and is dependent on the gyromagnetic ratio of the nucleus and the mobility of 
the lattice [9]. Not only are the spins of nuclei in the presence of an external magnetic field 
influenced by components of the lattice field, but also by neighboring nuclei with identical 
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precessional frequencies but differing magnetic quantum states. Though there is no net change in 
Boltzmann distribution of the nuclei, a nucleus in the lower energy level will be excited while an 
excited nucleus relaxes to the lower energy state. The average time it takes for the higher energy 
state nuclei to relax to a lower energy state with respect to neighboring nuclei is termed 
transverse relaxation time T2 [9].   
 Because the detection sensitivity of MRI is low, it often requires a contrast agent to 
enhance the signal intensity related to the relaxation rate of water protons [8]. The term 
relaxivity describes how effective a contrast agent is at enhancing the signal intensity by 
shortening proton relaxation times. Contrast agents influencing the relaxation times of water 
protons must be paramagnetic, those found amongst the transition metals and lanthanides, 
meaning they possess a number of unpaired electrons. Here, proton relaxivity is directly 
proportional to the efficiency of the paramagnetic ion to enhance the relaxation rate of water 
protons [8]. Gadolinium, bearing seven unpaired electrons, has been found to exhibit the 
strongest effect of all elements on T1. This is due to the dipole-dipole interactions between 
proton nuclear spins and the fluctuating local magnetic field caused by the unpaired electron 
spins of gadolinium [8]. Because free ions of heavy metals are toxic, lanthanides are typically 
complexed with a suitable metal chelator/ligand. When the metal is bound to the chelator, it 
gives rise to a contrast agent capable of influencing water relaxation.   
1.1.3. Factors Contributing to MRI Relaxivity 
There are a number of molecular parameters of contrast agents that govern relaxivity: 
rotational diffusion, inner- and outer/second-sphere hydration (q), water exchange rates (kex), 
ion-proton distances, and the electronic properties (Tie) of the paramagnetic ion [8]. The strength 
of the applied magnetic field (B0) and solution viscosity also play a role in relaxation processes. 
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Proton exchange rate, rotational correlation time, electronic relaxation times, Gd-proton 
distance, and hydration number directly influence the inner sphere proton relaxivity [8]. If the 
proton exchange is very slow relative to the relaxation rate of the coordinated protons to 
gadolinium, then it will become a limiting factor, hampering optimal relaxation. If the proton 
exchange is fast relative to the coordinated protons, proton relaxivity will be largely determined 
by the relaxation rate of the coordinate protons [8].  
Maximum relaxivity is attained when the correlation time (τci) equals the inverse proton 
Larmour frequency (ωi) [8]. The correlation times characteristic of the relaxation processes are 
as follows:  
                      1/τci = 1/τR + 1/Tie + 1/τm = ωi, where i = 1, 2  [8].   (Equation 1.4) 
More importantly, the rotational correlation time (τR), proton exchange (kex = 1/τm), and 
electronic relaxation rates (T1,2e) must be optimized simultaneously to achieve maximum 
relaxivities. Equation 1.5 addresses the effects of inner sphere relaxivity and how manipulation 
of its terms can increase the overall relaxivity of a contrast agent. 
r1IS = (q/[H2O])/ (T1m + τM) [8, 10]       (Equation 1.5) 
where r1IS is the relaxivity due to the inner sphere of water surrounding a paramagnetic metal 
ion, q is the hydration number, [H2O] is the water concentration in mM, T1m is the T1 of the 
water hydrogen in the inner sphere, and τM is the water residency time (τM = 1/kexchange of water 
in the inner sphere). This equation reveals that an increase in hydration (q) or decrease in T1m or 
τM can increase the overall relaxivity of a contrast agent [10]. However, the FDA approved 
gadolinium-based contrast agents have not effectively optimized these parameters.  
1.2. Commercial MRI Contrast Agents and Development 
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Currently, it has been estimated that 40-50% of all MR images are supplemented with a 
contrast agent [11]. Gadolinium-based contrast agents are implicated to achieve a number of 
these images. The six FDA approved commercial gadolinium-based MRI contrast agents are T1-
weighted agents, meaning they yield brightened images when introduced into a system (Figure 
1.4).  
 
 
Figure 1.4. FDA Approved Commercial Contrast Agents [12]. 
 
The basic chelate design ranges from linear to acyclic structures. Because of their enhanced 
thermodynamic stability and kinetic inertness, Gd3+-based MRI contrast agents derived from 
DOTA-like macrocyclic ligands have advantages over their linear counterparts (DTPA) [13]. 
Overall, these small molecular Gd-chelates maintain relaxivities of 4-6 mM-1 s-1 [14]. However, 
these agents have theoretically attainable relaxivity values of over 100 mM-1 s-1 (Figure 1.5A). It 
has been proposed that they fail to reach their maximum relaxivity due to their fast rotation time 
(100 ps) and slow water exchange in the inner sphere (Figure 1.5B) [3, 8].  
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Figure 1.5. The need for improved MRI gadolinium-based contrast agents. (A) Low relaxivity of 
commercial contrast agents compared to theoretical values. (B) Explanations for low observed 
relaxivity for commercial agents [7-8, 15]. 
 
Furthermore, the aforementioned contrast agents are only effective at high concentrations 
(>0.1 mM) [10]. Currently, the average clinical injection dosage of commercial contrast agents is 
approximately 500 mM/kg at an injection rate of 2-3 mL/s to achieve high sensitivity to the 
changes in water relaxation [14]. Even higher doses are required for imaging of blood vessels in 
Magnetic Resonance Angiograpy (MRA) [14]. Because of their small size, the systemic 
retention time of these agents is relatively short, maintaining a half-life of 1.5-2 hours in healthy 
adults and thus requiring a large dose to achieve an enhanced image [14]. However, in patients 
with kidney disease, the renal clearance is significantly decreased. Studies have shown that 
kidney-impaired patient exposure to gadolinium-based contrast agents has been linked to local 
necrosis at the injection site and nephrogenic systemic fibrosis (NSF) or nephrogenic systemic 
dermopathy (NSD) due to their weak binding affinity to gadolinium leading to the release of free 
gadolinium in the body and the accumulation of the contrast agent in the kidney (lack of proper 
excretion) [14].  
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Figure 1.6. Visible symptoms or signs of NSF/NSD [16-17]. 
 
NSF/NSD is a life-threatening disorder that may develop over a short period of days to several 
weeks (full development) [18]. As shown in Figure 1.6, it is characterized by swelling and 
tightening of the skin, usually limited to the extremities, and severely affected patients may be 
unable to walk, or fully extend the joints of their arms, hands, legs, and feet [18]. More 
specifically, the release of free gadolinium correlated with NSF has been known to cause many 
toxic systemic effects such as inhibiting calcium-flux-dependent physiological processes, 
blocking many voltage-gated calcium channels at nano- to micro-molar concentrations, and 
depressing the reticuloendothelial system [14, 19]. For this reason, in May 2007, the FDA issued 
a black box label warning to be placed on five of the six approved gadolinium-based contrast 
agents (with the exception of Dotarem®) in the United States, warning health professionals and 
patients of the association between the use of gadolinium-based contrast agents and NSF [20]. 
Because of their low dose efficiency due to low relaxivity and to low retention time and health 
hazards, there has been considerable effort to effectively improve contrast agent design and 
enhance the sensitivity of MRI devoid of such toxic effects. Agents with higher relaxivities and 
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optimal retention times can be detected at lower doses, providing greater signal contrast images 
at equivalent doses to commercial compounds with lower relaxivity [10]. 
The demand for the development of improved MRI contrast agents has become increasingly 
widespread. The two primary approaches taken by the scientific community to increase 
molecular relaxivity are optimization of the aforementioned molecular parameters that govern 
relaxivity and linking multiple gadolinium tetraazacyclododecanetetraacetic acid (DOTA) or 
diethylenetriaminopentaacetic acid (DTPA) complexes together (Figure 1.7) [10].  
 
Figure 1.7. Current MRI contrast agent development. 
 
These newly developed classes of contrast agents predominantly address the rapid rotational 
time of commercial agents by covalently linking chains of Gd-DTPA or Gd-DOTA to larger 
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biomolecules such as dendrimers, carbon nanotubes, nanoemulsions, liposomes, micelles, or 
proteins [21]. However, while these agents address the overall rotational time associated with 
molecular tumbling in solution, they do not achieve significantly higher relaxivities than the 
commercial analogues due to their intrinsic internal mobility and restricted water exchange rate 
[3]. Furthermore, their large particle size (10-100 nm) prevents them from being properly 
excreted from the body, raising greater toxicity concerns of gadolinium-based agents. As a 
result, a novel class of protein-based MRI contrast agents has been designed with high dose 
efficiency due to higher relaxivity, strong metal stability, and optimized pharmokinetics.  
1.3. Criteria for Contrast Agent Design  
Because contrast agents have the potential to be invaluable clinical probes for enhancing 
magnetic resonance images, it is of crucial importance to design an agent with a high relaxivity, 
strong binding affinity to gadolinium versus other physiological metal ions, and high metallo-
structural stability. The achieved higher relaxivity agent will not only improve the sensitivity of 
MR imaging, but also greatly reduce the amount of agent necessary to achieve significant 
contrast. Thus, the dose efficiency of the contrast agent is increased, providing higher contrast 
capability due to the incorporation of multiple designed gadolinium-binding sites into a scaffold 
structure and to obtaining an optimal τR in the nanosecond range. The strong binding affinity of 
the designed contrast agent to gadolinium will confer high metal selectivity to avoid potential 
adverse competition from other systemic metals and alleviate many of the toxic concerns 
associated with the release of free gadolinium into the system. Furthermore, heightened 
structural tolerance of mutations, high blood serum stability, and high solubility will reduce the 
potential instability of the scaffold contrast agent design. To add to the previously mentioned 
determining factors in design, the developed class of contrast agents must have no reported 
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interactions with other biomolecules, possess an optimal systemic retention time to successfully 
acquire an MR image, and be properly excreted via the kidneys or liver metabolism. 
1.4. Theory Preceding the Development of Protein-Based Contrast Agents 
Dr. Jenny Yang’s lab of Georgia State University has developed a novel approach to 
designing improved contrast agents via protein engineering. Protein-based MRI contrast agents 
offer a number of advantages compared to the aforementioned commercial analogs. To improve 
relaxivity, proteins can be modified to achieve an optimal metal-site rotational time of 10ns, 
optimal hydration of inner and second-sphere hydration, and optimal water exchange rates of 1-
30ns [3, 8]. The obtained higher relaxivity will improve the dose efficiency associated with 
gadolinium-based MRI contrast agents. Therefore, a lower concentration and volume of agent 
will be required to significantly improve the contrast to noise ratio of MR images, reducing the 
potential for the toxic effects associated with NSF/NSD. Their modifiable, compact molecular 
size (12 kDa) is suitable for sufficient intravascular distribution and easy renal excretion. 
Additionally, choosing a stable host protein tolerant of various mutations, affords the opportunity 
to design gadolinium-binding sites into its structure and confer metal selectivity via tuned metal 
binding affinity [3]. Improved solubility and reduced immunogenicity can be achieved by 
covalently attaching polyethylene glycol (PEG) chains to lysine or cysteine residues of the 
protein [22]. Using this approach to develop improved agents, Dr. Yang’s lab previously 
designed and conducted significant studies on Class ProCAi-CD2 agents (i = 1, 2, 3….9). These 
agents were developed through the introduction of single high-coordination gadolinium binding 
sites into stable CD2 protein using amino acid residues and water molecules as metal 
coordinating ligands [3]. The designed proteins showed strong selectivity for gadolinium over 
physiological metal ions such as calcium, zinc, and magnesium, exhibited a 20-fold increase in 
15 
 
T1 and T2 relaxation rate values over the conventional small-molecule contrast agents, e.g., Gd-
DTPA, and possessed stronger contrast enhancement and longer blood retention time than Gd-
DTPA in mice models [3]. With a new generation of contrast agents on the horizon, we hope to 
address the following question: Can we design multiple gadolinium-binding site agents to further 
increase contrast agent dose efficiency, increase stability, and reduce toxicity?   
1.5. Designed Multi-Binding Site Contrast Agents by Protein Engineering 
Dr. Jenny J. Yang’s lab specializes in two approaches to studies of calcium-binding proteins, 
the design and grafting approaches. The design approach involves site-directed mutagenesis to 
tune metal-binding affinities of calcium-binding proteins, conserving the number of amino acids 
in their primary sequence and maintaining their structural integrity. This approach was created in 
order to “develop a general methodology to design metal binding sites with high coordination 
numbers such as calcium and lanthanides, understand the mechanism of calcium-regulated 
biological process such as ligand-induced conformational changes in cell adhesion, and monitor 
calcium signaling in vivo” [23]. The grafting approach engineers an EF-hand calcium-binding 
loop into a protein to understand “site-specific metal binding affinity and selectivity of 
individual calcium binding motifs and to estimate the contribution of conformational change and 
cooperativity between paired EF-hand motifs” [23].  
Using the design approach, two gadolinium-binding sites were engineered into a stable host 
protein, which in its native state, has little to no reported interactions with other biomolecules. It 
is with great hopes that the increased number of binding sites will enhance the measured 
relaxivity compared to commercial agents, and thus improve the dose efficiency. Provided the 
binding affinity of gadolinium to the protein is significantly strong, the toxic effects associated 
with the release of free gadolinium into the system are greatly reduced. 
16 
 
1.6. Parvalbumin as an Excellent Scaffold for Engineering Multiple Gadolinium Binding Sites 
Parvalbumin is a small, 12 kDa acidic protein ubiquitously distributed throughout the 
vertebrate phylum [24-25]. The mammalian form is found in fast twitch muscle fibers, neuronal 
cells, and several endocrine glands [25]. Furthermore, parvalbumin has two isoforms: α and β. 
Though both forms have a conserved helix-turn-helix motif, the α-form maintains 109 amino 
acids and is believed to serve mainly as a cytosolic calcium-buffering protein with no known 
interacting partners [26-27]. This six α-helical protein, helices termed A through F, contains 
three EF-hand motifs, only two of which functionally bind calcium (CD and EF sites) (Figure 
1.8). The β-form, or better termed oncomodulin, maintains 108 amino acids, functioning more so 
as a calmodulin-like enzyme ―― often active during cellular proliferation [24, 27]. This form 
of parvalbumin possesses two different metal binding domains, one calcium specific and one 
calcium/magnesium mixed site [27]. For the purposes of this project, we will mainly focus on 
studies of the rat derived α-form. 
 
Figure 1.8. Pymol structure of rat-derived α-parvalbumin. 
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The CD site EF-hand motif of parvalbumin is modified through single mutations within a 
calcium-binding site. Maintaining pentagonal bipyramidal geometry (Figure 1.9), its residues 1, 
3, 5, 7, 9, and 12 are the conserved residues subject to mutagenesis [28]. Because calcium and 
gadolinium have comparable ionic radii and gadolinium, it is with great hopes that the increased 
charge of gadolinium will allow mutants to bind this metal with a much larger affinity than 
calcium. To enhance gadolinium-binding affinity and allow for experimental analysis, various 
mutations were introduced into the binding domains of parvalbumin (Figure 1.9).  
 
Figure 1.9. Summarizing the CD and EF binding domains of α-parvalbumin and their pentagonal 
bipyramidal geometries. 
 
Residue 103, located outside the EF binding domain, was mutated from phenylalanine (F) to 
tryptophan (W) in order to complete terbium fluorescence experiments. Residue 56, located in 
position five of the CD EF-hand binding site, was mutated from serine (S) to aspartic acid (D) to 
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increase the proteins gadolinium-binding affinity. Residue 60, also located in the CD binding site 
but in position nine, was mutated from glutamic acid (E) to aspartic acid (D) to increase 
gadolinium-binding affinity and allow for the incorporation of a water molecule into the binding 
site. This incorporation should theoretically enhance the water exchange rate associated with the 
gadolinium-binding site and increase the relaxivity. The same can also be said for residue 99, 
located in the EF binding site, mutation from glycine (G) to aspartic acid (D). It is proposed that 
these mutations will not perturb the conformational fold and can effectively bind gadolinium 
with little negative competition from calcium or other biological metal ions at their respective 
physiological concentration. However, this must be further investigated in future experiments. 
Single and double mutations were introduced into the metal binding sites to observe the intrinsic 
metal selectivity properties of mutant forms of parvalbumin. 
In this thesis, only single mutant forms of parvalbumin were studied. The significance of 
each mutation was previously discussed. Here, ProCA-30 represents wildtype parvalbumin. 
ProCA-31 is often referred as pseudo-wildtype parvalbumin because it bears a F103W mutation. 
ProCA-32 bears a S56D and F103W mutation. ProCA-33 encompasses an E60D and a F103W 
mutation. Collectively, these mutant proteins, or rather contrast agents, comprise four of many 
members of Class ProCA-3 agents (Table 1.1).      
1.7. Overview of Objectives 
In order to understand the key determinants for calcium-binding affinity and metal 
selectivity, the initial objective is to characterize the folding and metal-binding properties of 
parvalbumin. Based on the differentiation between 54 amino acid sequences, the human and rat 
α-forms maintain conserved residues within their EF-hand binding sites. Thus, characteristic in 
vitro studies of the rat derived form can allow one to draw conclusions about the functional 
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properties of the human form. The short-term goals of this project are to 1) isolate pure, 
functional rat parvalbumin (rPV) and its mutagenic components, 2) perform structural studies of 
rPV and its mutants by circular dichroism, and 3) complete calcium titration and metal binding 
competition experiments using fluorescence. The long-term goal is to control protein function by 
tuning metal binding affinities and eventually develop rPV and/or its mutants as site specific 
diagnostic and therapeutic MRI contrast agents.  
As part of this new class of MRI contrast agents, the engineered mutagenic form of 
parvalbumin will have improved relaxivity through the binding of gadolinium and exhibit strong 
stability against pH changes. Moreover, it should be structurally tolerant of mutations, have a 
selective binding affinity for gadolinium, and maintain a molecular size suitable for intravascular 
distribution and easy renal excretion [3]. Coupled with low toxicity and high solubility, the 
ability to mass produce pure quantities of this protein at reduced costs will prove advantageous. 
This thesis will focus primarily on the expression and purification, metal-dependent structural 
changes, and relaxivity of four members of Class ProCA-3. 
In chapter 2, the methods implemented for studies of Class ProCA-3 agents will be 
discussed. In chapter 3, the E. Coli expression and optimized purification of the designed 
contrast agents will be heavily expounded upon. In chapter 4, structural analysis of the purified 
agents in the presence of magnesium, calcium, gadolinium, and terbium and the effect that salt 
ions play on the structure will also be discussed. Chapter 5 will detail the measured in vitro 
relaxivities of Class ProCA-3 agents and their binding mode with gadolinium. Chapter 6 
discusses the significance of this thesis and the future application of Class ProCA-3 agents. The 
discussed members of this class are summarized in Table 1. 
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Table 1.1. Summary of the discussed members of Class ProCA-3 agents. 
Designed 
Contrast Agent  
Mutation  Location  Molecular 
Weight  
Pro CA-30  N/A  N/A  ~ 11.925 kDa  
ProCA-31  F103W  Just outside EF 
site  
~ 11.964 kDa  
ProCA-32  S56D, F103W  CD site (pos. 5) ~ 11.992 kDa  
ProCA-33 E60D, F103W CD site (pos. 9) ~11.950 kDa 
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2. MATERIALS AND METHODS 
2.1. Cloning and Transformation 
The DNA sequences for expression of the aforementioned contrast agents were cloned into 
pET-22b(+) by senior PhD student David Xue. The experimental details outlined in this thesis 
began at the level of transformation. Transformation is a commonly used technique to introduce 
genetic alterations into a host cell through the uptake of foreign DNA [29]. More specifically, 
the gene encoding for parvalbumin and its mutants were inserted into the pET-22b(+) vector 
between the Nde I and Xho I restriction enzyme sites and collectively transfected into E.Coli 
BL-21 pLys cells. (Figure 2.1).  
 
Figure 2.1. pET-22b(+) vector for Class ProCA-3 overexpression [30]. 
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This particular bacterial system is ideal for overexpression of the designed proteins because 
it has the ability to produce large amounts of RNA, amplifying the translation of wildtype or 
genetically engineered mutant genes [29]. A volume of 0.5 μL of desired mutant DNA was 
mixed with 50 μL of thawed E. Coli BL-21 pLys competent cells with a pipette using an “up and 
down” pipetting technique and placed on ice for thirty minutes. The samples, including the 
negative controls containing only competent cells, were placed in a 42 ºC water bath for 90 
seconds and placed on ice for an additional 2 minutes. A volume of 50 μL of LB was added to 
the samples and placed in the incubator at 37 ºC for 30 minutes. The samples were then streaked 
out with sterile L-shaped spreaders onto LB ampiscillin plates and left in the 37 ºC incubator 
overnight. The following morning yielded evidence of a large number of isolated colonies 
containing the transfected parvalbumin plasmid. One colony of each variant would be later used 
for innoculation. 
2.2. Protein Overexpression 
2.2.1. Pilot Expression 
A recurrent problem with the purification of soluble, tagless proteins, such as those of Class 
ProCA-3 agents, is the inability to eliminate DNA/RNA contamination. It is well known that 
insoluble proteins are effectively isolated from coexisting nucleic acids via inclusion body 
formation. Therefore, to improve the purification process and increase the yield of isolated 
protein, pilot expression procedures were implemented with hopes of extracting ProCA-30 and 
its mutants from the inclusion bodies, since DNA normally lies in the supernatant following 
centrifugation of cell lysate. It has been proposed that certain bacterial strains have a preference 
to form more inclusion bodies than others at a specific temperature. Therefore, choosing one of 
these strains to express the protein might allow us to extract it from the cell pellet. In an attempt 
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to isolate the protein from nucleic acids following cell lysis, the pilot expression protocol 
modified from Invitrogen’s pRSET A, B, C protocol manual was used to transform and express 
ProCA-30 in three different strains using two different concentrations of isopropyl β-D-1-
thiogalactopyranoside (IPTG) (0.5 and 1 mM). The cell pellet following expression was 
fractionated by incremental exposure to dry ice and analyzed by SDS-PAGE analysis to 
determine whether PV was present in the inclusion body for the reasons previously stated.  
2.2.2. Innoculation 
A predetermined volume of Luria Bertani (LB) medium was prepared and autoclaved at 15 
psi for 1 hour at 121 °C. Traditionally, two 1L flasks and one 250 mL flask were subjected to 
this sterilization process and allowed to cool for the overexpression of each ProCA-3 agent. In 
order to effectively overexpress each variant, an initial overnight growth of its cellular 
expression system must be achieved. One freshly transfected colony was immersed in a 250 mL 
culture of sterilized Luria Bertani (LB) medium containing 100 µg/mL of ampiscillin. Great care 
was taken to minimize contamination by use of a sterilized inoculating loop and by performing 
the transfer of clone to LB flask near an open flame. The flask was then placed in an 
environmental shaker to incubate overnight at 37 °C at a speed of 220 to 230 rpm. The following 
morning yielded a cloudy solution marked by cell growth. These cells were later to be 
transferred to a freshly sterilized LB-ampiscillin medium for optimal cell growth and eventual 
overexpression of the desired mutant.  
 
2.2.3. Overexpression 
A 50 mL volume of overnight culture was added to each of two 1L flasks of fresh media 
containing 100 µg/mL of ampiscillin. The two 1L flasks were incubated in a 37 ºC shaker at a 
speed of 220 to 230 rpm, allowing cellular growth to continue. Following induction of the 
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system with IPTG to overexpress the desired protein, the cells were allowed to grow for 
approximately three to four hours before reducing the incubation temperature to 25 °C at the 
same speed for overnight expression. The following morning, the cultured media was subjected 
to centrifugation and the cell pellet was isolated and frozen until purification methods were 
implemented. 
Using Shimadzu UV-Visible Spectrophotometer (UVP), the optical density of the rapidly 
growing cloned cells immediately before induction (0.6000 to 0.8000 more) with inducer IPTG 
and at various time points after induction was observed and recorded at 600 nm. The absorbance 
readings were recorded and plotted in the Kaleidagraph 3.5 program to chart cellular growth. 
Then the samples used for the UVP were saved and spun down in microcentrifuge tubes. The 
supernatant was poured off and the cell pellet containing the targeted mutant was resuspended in 
a sample buffer containing dithiothreitol (DTT) and beta-mercaptoethanol, which reduce the 
disulfide bridges stabilizing the  protein’s tertiary structure, and sodium dodecyl sulfate (SDS), 
and anionic detergent that binds strongly to and denatures the protein [25]. The samples were 
boiled for ten minutes and an SDS-PAGE gel analysis was conducted. The protein is fully 
denatured by this gel electrophoresis experiment and opens up in a rod-shaped form with a 
number of negatively charged SDS molecules along the polypeptide chain, one SDS molecule 
for every two amino acid residues of the mutant [25]. The gel was run using a marker of known 
molecular weight (68, 29, 14.3, and 6.5 kDa) to chart where the target contrast agent (~12 kDa) 
was located in the resolving portion of the gel following its migration through the stacking 
portion, which “concentrates the protein sample into a sharp band before it enters the main 
separating gel…allowing relatively large sample volumes of the mutant (10 μL) to be applied to 
the gel without any loss of resolution” [31]. Once the samples had completely migrated to the 
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bottom of the resolving portion of the gel, the entire gel was stained with a Coomassie blue 
reagent and destained with a buffer containing methanol, acetic acid, and deionized water. The 
protein bands are visible after destaining the gel. It is generally accepted that a “very faint 
protein band is equivalent to about 0.1 μg of protein” [31]. Figure 2.2 summarizes the expression 
procedures implemented.  
1 colony
250 mL fresh LB
100 mg ampicillin
Shake overnight at 
37 C
50 mL LB 1 L fresh LB 
100 mg ampicillin
Shake at 37 C to the 
desired O.D. of 0.6 to 
0.8 at 600nm
Transfer
1mM per 1L LB
IPTG
Overexpress 
protein overnight 
at 25ºC
Centrifugation at 
7K, 4°C, 30 
minutes
Collect cell 
pellet and 
store at -20°C
Expression Procedure:
Add
Transformation
Induction
pET 22b‐CA3 into 
E. Coli
BL‐21 (De3) pLys 
competent cells
 
Figure 2.2. Summary of the Expression Procedures for ProCA3 Agents. 
 
The most significant advantage of the overexpression of a recombinant protein is the ability 
to facilitate purification of high quantities of product. Following a collection of the cell pellet 
containing the desired protein from the cultured LB media, purification schemes using 
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sonication/French Press, nucleic acid precipitation, and ion exchange chromatography (IEC) 
were implemented to effectively extract the variant from the cells with a high degree of purity. 
2.3. Tagless Purification 
2.3.1. Sonication and French Press 
In order to extract the contrast agent from the cultured E. Coli cells, their phospholipid 
bilayer must be fractionated. There are two commonly used techniques to achieve this effect: 
sonication and French press. Sonication is the act of applying high energy sound waves to 
disrupt cell membranes and release cellular contents (sonoporation) [32]. Due to its simplistic 
ease of operation, the sonicator is much easier to use when you have many samples. 
Additionally, it gives a sample in a water bath an even and consistent vibration, allowing one to 
achieve the same amount of cell breakage in each sample [32]. French pressure cell press, or 
French press, is an apparatus used in biological experimentation to disrupt the plasma membrane 
of cells by passing them through a narrow valve under high pressure [33]. Once past the valve, 
the pressure drops to atmospheric pressure and generates shear stress that disrupts the cells. 
French Press is more efficient and doesn’t generate heat when breaking cells, but it has a 
minimum volume requirement (500 µL) [33]. Depending on the volume of protein expressed, 
researchers may prefer one over the other. There has been no notable difference in efficiency 
between the two methods for the purposes of these experiments so both were used 
interchangeably to lyse the cells.  
The cell pellet from the expression of a target protein was thawed in a cool water bath and 
resuspended in 30 mL of 10 mM Tris/HCl pH 7.4 buffer. The mixture was then vortexed with 
100 mM phenylmethanesulphonylfluoride (PMSF), a serine protease inhibitor, and separated 
into two 15 mL volumes to prepare for sonication. Protease inhibitors are necessary if the protein 
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has increased susceptibility to cleavage by a variety of proteases in solution. They help preserve 
the yield and quality of purified protein. There are four groups of proteases: serine, cysteine, 
aspartic and metallo-proteases. Based on protein sequence and published data, one can determine 
which type of protease inhibitor is best for the purification of his or her protein. The best 
protease inhibitor to be used for parvalbumin purification methods was one of serine derivation. 
Following its addition, each sample of protein was sonicated six times for 30 seconds, with one 
minute cooling increments. The mixture was then centrifuged at 17K for 30 minutes. The 
supernatant containing the soluble variant protein was collected and the cell pellet was 
discarded. Samples of both the supernatant and cell pellet were taken for SDS Page gel analysis 
by the previously described method within the expression protocol. 
2.3.2. Nucleic Acid Precipitation 
In efforts to isolate the soluble variant via tagless purification methods, DNA and RNA 
contamination must be removed from the supernatant. A concentration of 1.3µM of 
benzonuclease- MgCl2, an endonuclease and its cofactor that degrades all forms of DNA and 
RNA while having no proteolytic activity, was added to the supernatant overnight at 4 ºC. 
Endonucleases compose a class of restriction enzymes produced by bacteria that typically 
recognize specific 4- to 8-base pair palindromic sequences, called restriction sites, and then 
cleave both DNA strands at this site. Thus, the choice for endonuclease type was made based on 
the sequence of the pET-22b(+) vector. 
Previous experiments conducted prior to the Summer 2009 semester were done to determine 
which concentration of streptomycin sulfate (1%, 3%, 5%, or 10%) was optimal for the removal 
of nucleic acids and other proteins not thermally stable at high temperatures. It was found that 
5% streptomycin sulfate concentration is optimal for nucleic acid precipitation from the protein 
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supernatant following overnight cleavage of nucleic acids with benzonuclease. Thus, the process 
of precipitation began with adding 5% streptomycin sulfate, a nucleic acid precipitant, to the 
solution overnight at 4 ºC. The supernatant was centrifuged and the cell pellet was frozen while 
subsequent steps of the procedure were applied to the resulting supernatant containing the 
soluble contrast agent. Incubation in an 85 ºC water bath for 10 minutes and immersion in an ice 
bath allowed for a visible precipitation of fragmented nucleic acids and proteins lacking 
thermostability at such a high temperature. For thermostable proteins, the addition of nucleic 
acid precipitant aids in a higher yield from purification. The extent of protein precipitation is 
dependent upon the pH of solution and the ratio of precipitant to protein. Streptomycin sulfate is 
generally favorable over other commercially available precipitants such as, protamine sulfate and 
manganese chloride. One can also use varying concentrations of ammonium sulfate 
(concentration depends on properties of protein) to precipitate desired protein from a solution. 
The mixture was spun down again at 17K for 30 minutes, allowing one to collect the 
supernatant and freeze the cell pellet. To lower the salt concentration introduced into the protein 
supernatant system by streptomycin sulfate, the protein was dialysed in 10mM Tris/HCl pH 7.4 
overnight at 4ºC and for two 2 hour sessions under the same conditions the following day in 
freshly prepared buffer. Next, the supernatant was brought to a concentration of 5 mM EDTA to 
remove magnesium or calcium from the variant system over a period of one hour. Because the 
overall negative charge of the protein is reduced in the holo-form, the removal of metals from its 
binding site hopefully increases the protein’s affinity for the chromatographic methods of 
separation to be discussed. It was then filtered via a syringe through a 0.2 µM membrane and 
injected onto anionic Q-column using a FPLC system. Samples of both the supernatant and cell 
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pellet following cell lysis, nucleic acid precipitation, and dialysis were taken for SDS Page gel 
analysis by the previously described methods.  
2.3.3. Ion Exchange Chromatography 
The method of chromatographic column separation using FPLC is dependent upon the 
physical and chemical properties of a protein. If the protein carries a negative charge at the pH of 
buffer used, as in the case with parvalbumin and its variants, the Q sepharose column, an anionic 
binding column separating based on charge, is a great method for separation. Using an 
Amersham Biosciences FPLC system, a 10mL volume of diluted protein supernatant (ranged 
from a 1:10 to a 1:5 dilution of protein to Buffer A) was injected onto the Q column. Using 
Buffer A: 10mM Tris/HCl 5mM EDTA pH 8.5 and Buffer B: 10mM Tris/HCl 5mM EDTA 1M 
NaCl pH 8.5 combination, a modified FPLC separation program was implemented to elute the 
desired protein at 25% concentration of Buffer B.  
Initially, the contrast agent binds to the column with the introduction of Buffer A. 
Theoretically, any positively charged proteins at pH 8.5 with little affinity for the column will 
not bind to the column, maintaining a lower retention time than that of parvalbumin or nucleic 
acids. Thus, these proteins along with smaller fragments of nucleic acids will elute from the 
column in the first peak monitored by ultraviolet light at 260nm for mutants lacking a tryptophan 
and at 280nm for those containing a tryptophan. As the Buffer B concentration increases to 25%, 
the contrast agent will elute from the column in the second peak. The final peak eluted at 100% 
of Buffer B corresponds to nucleic acids that were initially present in the sample. Previous FPLC 
experimental conditions allowed for a second FPLC run during which Buffers A and B contained 
3mM Ca instead of EDTA. However, this step was eliminated to reduce the number of steps 
required to isolate the apo-form of the proteins for metal analysis via circular dichroism, 
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relaxivity, and fluorescence. It is well known that parvalbumin binds calcium with a high affinity 
and calcium. Additionally, with each successive step of the purification process, there are 
subsequent consequential losses of protein. Thus, the elimination of this step may also allow for 
isolation of a higher quantity of protein.   
The appropriate peak observed was collected from each injection. The desired protein 
fractions were concentrated down to a final resuspension in a 4 to 6 mL volume of fresh 10mM 
Tris/HCl chelexed at pH 7.4. The protein was then dialysed against 10mM Tris/HCl chelex 
overnight and then for two 2 hour increments the following day at 4˚C. Figure 2.3 and Figure 2.4 
summarize the purification procedures. 
 
 
Figure 2.3. Summary of ProCA3 Purification Procedures. 
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Figure 2.4. Summary of Purification Procedures Continued. 
 
2.3.4. Protein Concentration Calculation 
The UV absorbance of the concentrated protein was measured at its characteristic 
wavelength (previously mentioned) to calculate the final yield of protein and to verify its purity 
by comparing the spectra obtained to that of published data concerning the wildtype protein and 
F103W mutant. The concentration was calculated through use of the Beer-Lambert law, 
A = є c l,          (Equation 2.1) 
where A is the measured absorbance at 260nm (phenylalanine characteristic absorbance) for 
ProCA-30 and at 280nm (tryptophan characteristic absorbance) for ProCA-31, ProCA-32, and 
ProCA-33, c is the protein concentration, and l is the path length of the cell (1cm). The molar 
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extinction coefficient for ProCA-30 is 1600 cm-1 while that of the remaining members of Class 
ProCA-3 is 7200 cm-1 [25, 34]. The protein was then stored at -20ºC.  
 
Figure 2.5.Published UV spectrum of Parvalbumin. (A) Wildtype. (B) Parvalbumin-F103W; 
Dashed line, metal-free form; solid line, Ca2+ loaded form [25, 35]. 
 
2.4. Circular Dichroism 
Circular Dichroism (CD) is termed as the difference in the absorption of left- and right-
handed circularly polarized light of a molecule containing one or more chiral light-absorbing 
groups [36]. CD measured as a function of wavelength is termed CD spectroscopy. Circular 
polarized light is converted from linearly polarized light, the sum of two linearly polarized states 
(horizontal and vertical) at right angles to each other confined to a single plane, using a quarter-
wave plate [36]. This birefringent plate allows for the distinction between the refractive indices 
seen by horizontally and vertically polarized light, slowing one of the linear components of the 
beam with respect to the other so that they are one quarter-wave out of phase [36]. This produces 
a beam of either left- or right-circularly polarized light, due to variances in their speed 
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propagation in the medium. Projection of the resulting amplitude of the beam yields an ellipse 
instead of the usual line [36]. 
The chiral character of the molecules measured relies on their existence as non-
superimposable pairs of mirror images (enantiomers) [36]. Though the physical and chemical 
properties of a pair of enantiomers are the same, their optical activity varies and thus allows for 
delineation between the two using CD spectroscopy. Measurements carried out by the 
spectrometer in the near and far ultraviolet regions of the electromagnetic spectrum monitor 
electronic transitions of each chiral chromophore state of a molecule. Thus, the signal will vary 
as a function of wavelength and reflects an average of the entire molecular population [36]. The 
CD signal is positive if the left-circularly polarized light is absorbed to a greater extent than the 
right-circularly polarized light. The signal is negative if the reverse occurs.  
Though CD spectroscopy has been widely used in the study of various sizes of chiral 
molecules, it has been extensively implemented in the study of large biomolecules. More 
specifically, its role in secondary and tertiary structure determination of proteins has allowed 
researchers to observe conformational changes due to variations in environmental conditions 
such as temperature, pH, or interactions with other molecules such as metal ions. The secondary 
structure is observed in the far ultraviolet range of 250 to 190 nm while the packing interactions 
of the tertiary fold are observed in the near ultraviolet range of 350 to 250 nm [36]. An alpha-
helix absorbs negatively at 208nm and 222 nm and positively at 192 nm while a beta-sheet 
structure absorbs negative at 218 nm and positive at 196 nm and a random coil absorbs positive 
at 212 nm and negative at 195 nm [36]. 
Proteins are composed of amino acids and 19 of the 20 naturally occurring amino acids 
(exception is glycine) are chiral and thus allow for observation via CD spectroscopy. Protein 
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chromophores are divided into three classes: the peptide bond, the amino acid sidechains, and 
any prosthetic groups [36]. For example, disulfide group of cysteine is an inherently asymmetric 
chromophore as it prefers a gauche conformation with a broad CD absorption around 250 nm. 
Additionally, the three aromatic side chains that occur in proteins (phenyl group of Phe, phenolic 
group of Tyr, and indole group of Trp) also have absorption bands in the ultraviolet spectrum. 
However, in proteins, their contribution to the CD spectra in the far UV (where secondary 
structural information is located) is usually negligible [36]. Aromatic residues, if unusually 
abundant, can have significant effects on the CD spectra in the region < 230 nm, complicating 
analysis. 
Changes in CD signal stem from changes in protein structure. These changes are often 
observed in the presence of various metal ions. For example, previous studies conducted by A. 
Szent-Gyorgyi investigate the citric acid (oxygen metabolism) cycle (1941) in which subsequent 
electron transfers occur in eight proteins, which lead to the hypothesis that proteins act as 
conductors [37]. A group of researchers isolated and purified metal-doped (Cu2O, CdO and PbO) 
muscle protein from fish (Clarious batracus Lin.) and characterized its potential as 
semiconducting biopolymer [37]. Initial characterization studies observed secondary structure 
changes of the isolated protein in the presence of Cd, Pb, and Cu using CD (Figure 2.6). 
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Figure 2.6. CD spectrum of protein with and without metal-doped (a) pro, (b) pro-Cd, (c) pro-Pb 
and (d) pro-Cu [37]. 
 
The scientists wanted to ensure the structural dependence of the protein with the metal ion. 
From the figure, one can observe that helicity decreased as the metals of increasing size were 
added to the protein. The authors attributed this phenomenon to the slight weakening of the 
hydrogen bonds caused by the insertion of larger metal ions [37]. This figure indicates that the 
protein has undergone a simple transformation from twisted coil to alpha-helix. From this study 
and countless others, one can see the usefulness of CD as a tool to probe changes in protein 
structure. More specifically, this spectroscopic technique can be used to evaluate structural 
changes induced by the binding of the ProCA3 agents to various metals. 
The secondary structural changes, if any, of each agent in the presence of magnesium, 
calcium, gadolinium, and terbium were analyzed. The parameters for the CD instrument were set 
as follows: 0.5 nm data pitch, continuous scanning mode, 100 nm/min scanning speed, 1 sec 
response, 1 nm band width, 7 accumulation for the scans. Initially, the buffer 10 mM Tris/HCl 
(100 mM NaCl) chelex pH 7.4 was scanned. This spectrum was subtracted from the UV spectra 
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to follow. The second sample scanned consisted of the previous buffer system of the first sample 
containing 5 to 10 µM protein. The characteristic absorption of this alpha-helical protein was 
noted. The addition of calcium, gadolinium, terbium, or magnesium in this system for the 
consecutive samples was completed to observe any spectral changes in conformation. 
Appropriate background absorptions were subtracted for the samples with added metal. Analysis 
of the stability of the protein’s structure as well as its conformational behavior in the presence of 
varying metal environments can be analyzed. 
2.5. Fluorescence Spectroscopy 
The length of time necessary for each member of Class ProCA-3 to equilibrate with 
gadolinium for accurate measurement of relaxation times was unknown. Thus, fluorescence 
spectroscopy was used to determine the appropriate metal equilibration time for preparing the 
relaxivity samples for measurement. It is well known that the length of time required is heavily 
dependent upon the binding affinity of the protein to gadolinium. Assuming that the member of 
Class ProCA-3 displaying the weakest binding affinity to gadolinium will require the longest 
amount of time to reach metal equilibration, ProCA-31 was chosen as the test subject. It is 
important to note here that all dissociation constants were measured via terbium fluorescent 
metal competition experiments by Sr. PhD researcher David Xue.  
The parameters for an emission scan using the fluorimeter were set as follows: digital 
configuration, λexc- 552 nm (per manufacturer’s recommendation), λem.- 560-650 nm (per 
manufacturer’s recommendation), length: 90 nm, step size: 1 nm, integration: 0.2 seconds, 
averages: 1, and slit widths: excitation- 0.32 and emission-0.50. A stock sample of 100µM of 
ProCA-31 and 200µM of gadolinium was incubated at 37˚C over the following time points: 30 
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minutes, 3 hours, and overnight. Separately, a 10µM stock of Rhodamine-5N tripotassium salt, a 
weak calcium dye, was prepared in 100mM Tris/HCl 100mM NaCl chelex pH 7.44 (Figure 2.7). 
 
Figure 2.7. Chemical structure of rhodamine-5N tripotassium salt used in fluorescence titrations 
[38]. 
 
At the start of each time point, the fluorescent signal intensity of free 10µM Rhodamine-5N was 
measured. Then, a calculated volume of ProCA-31-Gd3+ from the stock sample was mixed with 
the 10µM Rhodamine-5N to yield a final concentration of 20µM ProCA-31 to 40µM gadolinium 
concentration in an 800µL volume. A subsequent scan of this sample’s increased fluorescent 
signal was measured (Figure 2.8). Next, increasing amounts of gadolinium was titrated into the 
system until free Rhodamine-5N became saturated, as indicated by the absence of change in 
increasing fluorescence intensity. Then, a predetermined concentration of EGTA was added to 
the system to chelate the metal bound both to Rhodamine-5N and protein and decrease the 
fluorescent signal back to the baseline of fluorescent intensity (Figure 2.8).  
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Figure 2.8. Fluorescence spectrum of free metal titration experiment. 
 
The pH of the dye stock sample, the stock sample, and the EGTA added sample was monitored 
to ensure that the pH values remained close to the original conditions of 7.44. The maximum 
intensity of each scan was recorded and substituted into the following equation to yield the 
concentration of free metal remaining in solution: 
[M]free, M = Kd( F – F0)/ (Fmax – F)  [38],         (Equation 2.2) 
where Kd represents the binding affinity of ProCA-31 to gadolinium (previously determined to 
be 1.04 x 10-11), F represents the maximum fluorescence intensity of the peak corresponding to 
the ProCA-31-Gd3+ complex and dye, F0 represents the EGTA treated sample that returns the 
signal to baseline, and Fmax represents the maximum intensity of the peak corresponding to the 
ProCA-31-Gd3+ complex and dye saturated with gadolinium [38]. The incubation time yielding 
the lowest concentration of free metal was chosen to be the standard time allowed for metal 
equilibration of future relaxivity samples. 
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2.6. Relaxometry 
The T1 and T2 values of protein and/or metal samples were measured using a Bruker 
Minispec combined with an mq60 NMR Analyzer at 37ºC, a temperature monitored and 
controlled by a digitally operated water bath, at 60MHz or 1.5 Tesla. Verification of the 
temperature was also obtained manually using an alcohol thermometer. The samples to be 
measured consisted of either a 10mM Tris/HCl chelex pH 7.4 (low salt) or 10mM Tris/HCl 
100mM NaCl chelex pH 7.4 (high salt) buffering system, in which varying concentrations (10 to 
50µM) of a desired protein was suspended. An amount of metal, either calcium or gadolinium, 
was added in a one to one or one to two concentration relative to the protein concentration to 
observe changes in relaxivity. Additionally, experiments were conducted using a fixed 
concentration of gadolinium and varying ProCA-3 concentration to determine whether the 
binding of the metal to ProCA-3 is one to one or one to two. The average relaxivity from this 
experiment is taken as the average of the relaxivity of ratios located in the plateau portion of the 
curve. The following equation was used to calculate the relaxivity with respect to each relaxation 
time:  
1/T1,2 = (1/T1,2 sample – 1/T1,2 buffer)/ [Gd3+]  [10].   (Equation 2.3) 
Using a Bruker Minispec application program, basic instrumental parameters were checked 
using a mineral oil sample. Following a daily check of the instrumental parameters (to be 
performed once per day of use), the instrumental gain was tuned using a buffer only sample. The 
gain value obtained for the T2 program was used for the T1 program. Each sample was measured 
in the following fashion: T2 first and then T1, with a 5 minute warming time for each sample at 
37ºC prior to measurement. Following collection of data, the percent of T1 and T2 signals were 
plotted in Kaleidagraph 3.5 as a function of time to chart the change in relaxation signal over 
40 
 
time. For fixed ratio experiments, the data obtained was plotted in Kaleidagraph 3.5 as protein 
concentration vs. 1/T1 or 1/T2 to yield R1 and R2 values. For varying ratio experiments at a 
fixed concentration of gadolinium, the data obtained was plotted in Kaleidagraph 3.5 as protein 
concentration vs. 1/T1 or 1/T2, yielding averaged R1 and R2 values from the plateau portion of 
the curve and allowing one to infer the binding mode of the contrast agent to gadolinium: 1 to 1 
or 1 to 2. By nature of design, we anticipate that the binding mode is 1 to 2. 
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3. EXPRESSION AND PURIFICATION RESULTS 
3.1. Background 
To obtain a large quantity of contrast agent for animal model studies and future clinical 
trials, it is extremely important to have a time-effective, cost conscientious, well established 
protocol for achieving a high yield of purified Class ProCA-3 agents. In this chapter, the 
expression results will reveal that each designed contrast agent of this class was successfully 
overexpressed using the aforementioned expression protocol in the chapter 2. Following 
improvements and modifications made to the established protocol for parvalbumin expression 
and purification, it will be later shown that members of Class ProCA-3 can be effectively 
isolated and purified. Studies were performed to improve the product yield by overcoming the 
limitations associated with the isolation of a tagless protein from nucleic acids coexisting in the 
supernatant following cell lysis. 
3.2. Expression Results 
As discussed in section 2.2.1, pilot expression procedures were implemented to analyze the 
cell strain and IPTG concentration optimal for overexpression of protein. Figure 3.1 indicates 
that the cells of all tested strains grew fairly well in LB media. Here, it’s evident that BL-
21(De3) pLysS and Tuner (De3) pLac I cell strains grew best prior to overnight incubation. After 
overnight growth, there seems to be no considerable difference in cellular growth amongst the 
different strains. Additionally, the varied concentrations of IPTG appear to have little to no effect 
on cell growth for all tested cell strains. 
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Figure 3.1. Cellular growth curve of pilot expression results. 
 
Unlike previous expression experiments, SDS-PAGE analysis reveals that the BL-21 
(De3) pLys strain did not overexpress the protein very well (Figure 3.2). The Rosetta pLysS 
expressed ProCA-30 at an intermediate level of expression compared to the enhanced 
overexpression in the Tuner pLacI strain. There appears to be little preference for overexpression 
between the two varying IPTG concentrations.  
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Figure 3.2. SDS-PAGE gel pilot expression results. 
 
Taking into account the previous expression experiments of ProCA-30, the BL-21 pLys 
(De3) strain at 1mM IPTG allows for expression exclusively in the supernatant. The Tuner strain 
allowed for expression both in the supernatant and inclusion bodies (Figure 3.3). This condition 
is not favorable as the protein from each location will have to be purified separately. Protein 
expressed in the supernatant will be in a soluble form and likely folded properly. The protein 
expressed in the inclusion bodies will likely not be properly folded. The Rosetta pLys strain did 
not yield any protein in the supernatant. It was decided to continue expression in the BL-21 pLys 
(De3) strain to simplify purification of the tagless protein. 
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Figure 3.3. SDS-PAGE gel results following pilot expression cell fractionation. 
 
ProCA-30 
Following successful transformation of pET-22b(+)-ProCA-30 into BL-21 pLys cells, the 
procedures implemented for expression were identical to those described in the materials and 
methods section. According to the increasing optical density of cell culture, the cloned cells 
containing the gene encoding for ProCA-30 grew very well (Figure 3.4A). This observation was 
further evidenced by the increasingly “cloudy” appearance of the cell culture as incubation time 
increased. SDS-PAGE gel analysis indicates that there was little desired ProCA-30 expressed 
prior to induction with IPTG (Figure 3.4B). Following induction, it is clear that the heavier 
bands on the gel for samples after IPTG addition as compared to the one before induction 
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indicate that not only did the cells receive the signal to begin expressing the variant in high yield 
but a significant amount of protein was overexpressed. There was only a slight difference in the 
density of bands on the gel before and after overnight growth following induction. This indicates 
that overnight growth at a reduced temperature did little to significantly enhance the 
overexpression of ProCA-30. However, this effect observed is not sufficient to modify the 
procedure and eliminate overnight growth. Further expression of ProCA-30 and its variants are 
necessary to make such a conclusive decision.  
 
Figure 3.4. ProCA-30 Overexpression. (A) E. Coli ProCA-30 cellular growth curve. (B) ProCA-
30 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media. 
 
ProCA-31 
Following successful transformation gene of pET-22b(+)-ProCA-31 into BL-21 pLys 
cells, the contrast agent was expressed according to the methods described in the materials and 
methods section. According to the increasing optical density of cell culture, the cloned cells 
containing the gene encoding for ProCA-31 grew very well (Figure 3.5A). Like the expression of 
ProCA-30, this observation was further evidenced by the increasingly “cloudy” appearance of 
the cell culture as incubation time increased. It appears that a small amount of ProCA-31 was 
expressed prior to induction. To provide an explanation for the faint bands in lanes 2 and 3 of the 
SDS-PAGE gel, it is important to note that the top closing the eppendorf tubes of samples from 1 
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and 3 hours after induction were not secure (Figure 3.5B). Therefore, these samples were diluted 
during the boiling step prior to running SDS-PAGE. Following induction, the heavier bands on 
the gel for 5 hr and overnight samples indicate that a significant amount of protein was 
overexpressed. There was little difference in the density of bands on the gel before and after 
overnight growth following induction. This indicates that overnight growth at a reduced 
temperature did little to significantly enhance the overexpression of ProCA-30. Still, this effect 
observed is not sufficient to modify the procedure and eliminate overnight growth. Further 
expression of ProCA-31 and the remaining members of Class ProCA-3 are necessary to make 
such a conclusive decision.  
 
Figure 3.5. ProCA-31 Overexpression. (A) E. Coli ProCA-31cellular growth curve. (B) ProCA-
31 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media. 
 
ProCA-32 
 pET-22b(+)-ProCA-32 was transformed into BL-21 pLys cells and expressed according 
to the procedures described in the materials and methods section. According to the increasing 
optical density of cell culture, the cloned cells containing the gene encoding for ProCA-32 grew 
very well (Figure 3.6A). SDS-PAGE gel analysis indicates that there was a fair amount of 
protein expressed prior to induction with IPTG (Figure 3.6B). There is little difference between 1 
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and 3 hour induced states. Furthermore, provided an equal amount of each sample was loaded 
onto the gel, overnight condition after induction yields slightly more desired protein when 
compared to 5 hours following induction. Overall, it is clear that a significant amount of protein 
was overexpressed during this expression experiment.  
 
 
Figure 3.6. ProCA-32 Overexpression. (A) E. Coli ProCA-32 cellular growth curve. (B) ProCA-
32 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media. 
 
ProCA-33 
pET-22b(+)-ProCA-33 was successfully transformed into BL-21 pLys cells. The 
procedures for expression were identical to those described in the materials and methods section. 
According to the increasing optical density of cell culture and the increasingly “cloudy” 
appearance of the cell culture as incubation time increased, the cloned cells containing the gene 
encoding for ProCA-33 grew very well (Figure 3.7A). Although SDS-PAGE gel analysis 
indicates that there was a small amount of protein expressed prior to induction, the increased 
density of bands on the gel for samples following induction indicate that a significant amount of 
protein was overexpressed (Figure 3.7B). Like ProCA-32 overexpression, there was a notable 
difference in the density of bands on the gel for 5 hour and overnight growth after induction. 
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This indicates that overnight growth at a reduced temperature enhances the overexpression of 
ProCA-33.  
 
Figure 3.7. ProCA-33 Overexpression. (A) E. Coli ProCA-33 cellular growth curve. (B) ProCA-
33 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media. 
 
3.3. Optimizing the Purification Protocol 
3.3.1. Old Purification Method and Its Limitations 
The original purification protocol was identical to the current protocol with the following 
exceptions: a 1% streptomycin sulfate concentration was used, there was no dialysis step 
introduced prior to injection of the supernatant onto the Q-column, the pH of the FPLC buffers 
was 7.4, the program for FPLC separation was not optimized, and a second FPLC run using 
another set of buffers introducing calcium into the system was introduced (Figure 3.8). 
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Sonicator (or Fr. Press)
Six 30 second increments 
with 1 minute on ice 
between each subjection 
(French press completed for 
a total of 3 trials)
Supernatant 
was collected 
and cell pellet 
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Allow solution to 
incubate at 4ºC 
overnight
Old Method of Purification:
1.33µM 
benzonuclease with 
its cofactor MgCl2
Add streptomycin 
sulfate and shake 
overnight at 4ºC
1% strep.
Supernatant was 
collected and cell pellet 
discarded
Centrifugation at 
17K, 4°C, 30 
minutes
Centrifugation at 
17K, 4°C, 30 
minutes
Condition 1
Buffer A‐ 10mM 
Tris/HCl, 3mM 
EDTA, pH 7.4 
Buffer B‐ 10mM 
Tris/HCl, 3mM 
EDTA, 1M NaCl, pH 
7.4
Condition 2
Buffer A‐ 10mM 
Tris/HCl, 3mM CaCl2, 
pH 7.4 
Buffer B‐ 10mM 
Tris/HCl, 3mM 
CaCl2,, 1M NaCl, pH 
7.4
 
Figure 3.8. Original purification protocol prior to modifications. 
 
 For simplification purposes, the expression gels pertaining to the purification results 
using the older protocol are not depicted. However, it’s important to note that the expression 
results from these experiments were comparable to those mentioned in the previous section. 
The results for each ProCA-3 member purified according to the original purification methods 
described in Figure 3.8 are as follows: 
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Figure 3.9. ProCA-30 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B) 
FPLC Condition 1 in the absence of calcium. (C) Left to Right: FPLC Condition 2 results in the 
presence of calcium and UV-Spectrum results of collected fractions. 
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Figure 3.10. ProCA-31 Old Purification Protocol Results. (A) SDS-PAGE from purification and 
FPLC Condition 1 in the absence of calcium. (B) FPLC Condition 2 results in the presence of 
calcium. (C) UV-Spectrum results of collected fractions. 
 
 
52 
 
 
Figure 3.11. ProCA-32 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B) 
FPLC Condition 1 in the absence of calcium. (C) FPLC Condition 2 results in the presence of 
calcium. (D) UV-Spectrum results of collected fractions. 
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Figure 3.12. ProCA-33 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B) 
FPLC Condition 1 in the absence of calcium. (C) FPLC Condition 2 results in the presence of 
calcium. (D) UV-Spectrum results of collected fractions. 
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There are several limitations to the old purification methods used to extract Class ProCA-3 
agents from an E.Coli cell pellet: Q-column overloading, high concentration of nucleic acids 
present in supernatant, inability to separate protein from nucleic acid due to inefficient FPLC salt 
gradient method, and loss of protein during the second FPLC condition when calcium is 
introduced into the system. As one can infer from Figures 3.9 -3.12, the purification gels reveal 
that the predominant protein injected onto the Q-column is the desired overexpressed variant. 
Prior to FPLC injection, there is little undesired protein present in the supernatant. At this stage, 
it was assumed that the predominant biomolecules present in the supernatant were the desired 
contrast agent and nucleic acids (verified by UV-spectrum). However, FPLC condition 1 (no 
calcium) and condition 2 (in presence of calcium) chromatograms clearly indicate that the 
proteins are not binding to the column well, eluting from the column before the salt gradient is 
introduced for both conditions 1 and 2 FPLC injections. This is also evidenced by the bands 
pertaining to the collected fractions at approximately 12 kDa on the SDS Page gels. Because 
nucleic acids are negatively charged in solution at pH 7.4, they have a higher affinity for anionic 
Q-column than the contrast agents. It’s possible that the column efficiency was reduced due to 
the inability of 1% streptomycin sulfate, supplemented with heat, to precipitate the substantial 
concentration of nucleic acids that coexist with the desired contrast agent in the supernatant prior 
to FPLC injection. Thus, the column became saturated with the high concentration of nucleic 
acids remaining in the supernatant and reduced the column’s capacity to bind the contrast agents. 
Additionally, it’s evident that the FPLC salt gradient may not be optimal for separation. It 
increases sharply to 70% NaCl and steadily to 100% NaCl. Because the members of Class 
ProCA-3 bind calcium very strongly, on the order of 10-9M, it is very difficult to achieve the 
apo-form of the variants for future analysis. Therefore, other than the consequential loss of 
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protein associated with an increase in subsequent purification steps, the second FPLC condition 
introducing calcium into the purification system is not ideal. Thus, modifications to this protocol 
will be devoted to increasing column capacity by cleaning the Q-column more efficiently with a 
combination of ethanol, 1M NaCl, deionized water, and Buffer A prior to injection and by 
decreasing the amount of nucleic acids coexisting in the supernatant. Furthermore, diluting the 
highly concentrated supernatant before FPLC injection and modifying the salt gradient of the 
FPLC program to allow for effective isolation of the desired contrast agent will significantly 
improve the purification yield. 
 
3.3.2. Streptomycin Variation to Reduce Nucleic Acid Concentration in the Supernatant 
The members of Class ProCA-3 agents are soluble variants that typically lie in the 
supernatant following cell lysis. It is well known that nucleic acids are also very soluble and lie 
in the supernatant. Because both nucleic acids and the variants of this class are negatively 
charged in solution, the primary goal is to isolate a pure, functional form of each contrast agent 
devoid of any “contamination,” including nucleic acids. More specifically, it was thought that 
the presence of a high concentration of similarly negatively charged nucleic acids in the 
supernatant injected onto the Q-column could possibly saturate the positively charged column 
and decrease its efficiency by interfering with the proteins’ optimal binding. For the purposes of 
this thesis, three variants of ProCA-30 were arbitrarily chosen reducing the concentration of 
nucleic acids in the supernatant: PV-S56D, PV-E60D, and PV-G99D.  
Prior to streptomycin treatment for purification, a 1mL sample of each mutant was treated 
with 1%, 3%, 5%, and 10% streptomycin sulfate to observe which concentration was optimal for 
the removal of nucleic acids and other proteins not thermally stable at high temperatures. The 
effects of concentrations of streptomycin sulfate above 10% were not investigated in efforts to 
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reduce the amount of “impurities” introduced into the purification schemes. Following treatment 
with streptomycin sulfate, the samples were incubated overnight at 4˚C per the purification 
protocol, and agarose and SDS gels were run on the samples the following day. Because SDS gel 
electrophoresis requires that samples be boiled with a loading buffer before loading onto the gel, 
the SDS-PAGE results are post boiling while the agarose gel samples were taken and run before 
boiling. The intensity of the agarose gel bands should be the same for each condition. However, 
the migration distance will vary with different streptomycin sulfate concentrations based upon 
how efficiently streptomycin sulfate binds the nucleic acids in the sample. SDS-PAGE results 
allow one to infer the degree of precipitation of thermally unstable proteins present in each 
sample. Using these tools, the optimal concentration of streptomycin sulfate used during the 
purification process can be approximated.  
PV-S56D and PV-E60D were overexpressed again according to previous expression 
protocols and were very successful. Once streptomycin sulfate was added, samples of PV-S56D 
and PV-E60D were analyzed (Figure 3.13). 
 
57 
 
 
Figure 3.13. Varying Strep. Treatment Conditions to S56D and E60D. (A) PV-S56D results. (B) 
PV-E60D results. 
 
Agarose gel results of PV-S56D reveal that the treatment of the supernatant before 
benzonuclease (BB) versus after the treatment (AB) yields a slight increase in fragmentation of 
the nucleic acids as evidenced by the more migrated band in the AB lane (Figure 3.13A). SDS-
PAGE analysis of these samples yields slightly less protein following the addition of 
benzonuclease because the boiling of samples required for SDS gel analysis may have facilitated 
the precipitation of thermally unstable proteins. It is important to note here that the striated bands 
on the SDS gel for 5% and 10% streptomycin treatment are typical results associated with SDS-
streptomycin sulfate experiments due to heat-facilitated precipitation of sample components. 
This pattern likely occurs at higher concentrations of streptomycin sulfate because more proteins 
are precipitated, making it more difficult for the bands to pull down during electrophoresis. To 
allow for more conclusions to be drawn from SDS gel analysis, the supernatant isolated from 
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centrifugation of these samples should have been run on the gel to avoid the negative effects 
associated with significant protein precipitation during SDS-PAGE. 
It appears that 1% streptomycin sulfate is optimal for PV-S56D nucleic acid precipitation 
because its band has a higher molecular weight than that of the other tested streptomycin sulfate 
concentrations (streptomycin binds to DNA yielding a higher molecular weight) shown in the 
agarose gel and it appears to have a reduced amount of undesired proteins (SDS gel) present in 
the supernatant following heat. Furthermore, the 1% cell pellet isolated from centrifuging the 1% 
streptomycin sulfate sample contains a comparable amount of nucleic acids, though at a smaller 
molecular weight. Due to a flaw in experimental design, the concentration of nucleic acids in the 
cell pellets from other tested streptomycin sulfate concentrations were not run on the gel and 
thus cannot be compared to the 1% cell pellet. This will be later addressed with PV-G99D 
experiments. Because the SDS gel results are not conclusive this experiment was repeated with a 
different variant of ProCA-30, PV-E60D.  
Like PV-S56D, the treatment of PV-E60D supernatant before benzonuclease (BB) versus 
after the treatment (AB) yields a slight increase in fragmentation of the nucleic acids as 
evidenced by the more migrated band in the AB lane (Figure 3.13B). It is unclear why SDS-
PAGE analysis of these samples yields slightly less protein following the addition of 
benzonuclease. Furthermore, it is unclear why the amount of nucleic acid for each streptomycin 
concentration sample differs. While nucleic acid concentration appears to be inconsistent for 5% 
and 10%, 1% and 3% appear to maintain comparable concentrations of nucleic acids. This may 
be due to human sample loading error. Nevertheless, based solely on the reduced distance of 
band migration for agarose gel electrophoresis and the reduced amount of undesired proteins 
(SDS gel) present in the supernatant following heat, it appears that 3% streptomycin sulfate is 
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optimal for nucleic acid removal. The absence of “band striations” at 10% streptomycin sulfate 
for this variant compared to that of PV-S56D may be related to the heterogeneous nature of the 
samples run on the SDS gel.   
PV-G99D was overexpressed very well and subjected to the varying streptomycin sulfate 
concentration experiment (Figure 3.14). Using a similar method of analysis as achieved with PV-
S56D and PV-E60D but implementing the boiling and centrifugation steps prior to gel analysis, 
it appears that 5% streptomycin sulfate is optimal for DNA precipitation from the supernatant of 
G99D (Figure 3.14). The reduction of nucleic acids present in the supernatant before and after 
heating and centrifugation is most significant at 5% streptomycin sulfate (lanes 8 and 9). 
Furthermore, the 5% cell pellet contains the highest concentration of nucleic acid isolated from 
the supernatant following heat and centrifugation. It’s important to note that heat significantly 
facilitates the precipitation of nucleic acids removed by precipitation. 
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Figure 3.14. PV-G99D varying streptomycin sulfate treatment agarose gel results. (A) 
Streptomycin screening for optimal conditions. (B) Changes in nucleic acid concentration at 5% 
streptomycin sulfate. 
 
 Overall, it appears that the streptomycin sulfate precipitation method is effective at 
reducing the concentration of nucleic acids in the supernatant. While the data from PV-S56D and 
PV-E60D insinuates that 1-3% streptomycin sulfate is optimal for binding to nucleic acids in the 
supernatant and facilitating their precipitation, it does not incorporate the use of heat and 
centrifugation into agarose gel analysis, which has shown to significantly decrease the 
concentration of nucleic acids in the experiment using PV-G99D. From the G99D experiment, it 
was found that 5% streptomycin sulfate concentration is optimal for nucleic acid precipitation 
from the protein supernatant following overnight cleavage of nucleic acids with benzonuclease. 
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This is evidenced by the reduced concentration of nucleic acids present in the supernatant 
following heating and centrifugation and the increase of nucleic acids present in the 5% cell 
pellet conditions. Therefore, the purification protocol was modified to use 5% streptomycin 
sulfate process for nucleic acid precipitation.  
3.3.3. Modified FPLC Program 
Previous FPLC experimental conditions allowed for a second FPLC run during which 
Buffers A and B contained 3mM Ca instead of EDTA. However, this step was eliminated to 
reduce the number of steps required to isolate the apo-form of the proteins for metal analysis via 
circular dichroism, relaxivity, and fluorescence. It is well known that the native form of ProCA-
30 binds calcium with a high affinity and it is difficult and time-consuming to remove the metal 
ions at such a high concentration of calcium previously used. Additionally, with each successive 
step of the purification process, there are consequential subsequent losses of protein. Thus, the 
elimination of this step along with an optimal salt gradient of separation, may allow for isolation 
of a higher quantity of protein.   
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Figure 3.15. Typical FPLC chromatogram of ProCA-3 agents by Q-column separation and the 
UV absorbance of each fraction. 
 
 Figure 3.15 depicts the characteristic chromatogram and UV absorbance spectra resulting 
from Q-column FPLC separation of ProCA-3 agents cell lysate. Each labeled peak directly 
corresponds to the numbers used to label the lanes on both the SDS-PAGE gel and the agarose 
gel. Here, the FPLC gradient was modified from a sharp increase to 70% NaCl and steady 
increase to 100% NaCl (old protocol) to final program specifications of column washing with 
15mL of Buffer A, a steady increase to 25% NaCl and then holding that concentration for three 
column volumes (15mL) before a sharp increase to 100% NaCl to elute any bound proteins or 
nucleic acids to the Q-column. This program was implemented on ProCA-30, ProCA-31, 
ProCA-32, and ProCA-33 (Figures 3.17-3.20). As one can infer from the broad peak at 260nm of 
the UV-spectrum corresponding to peak 1 and the absence of a band on the SDS-PAGE gel, peak 
1 is likely smaller fragments of nucleic acids and to a lesser degree of undesired protein that did 
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not bind to the column. Because the concentration of fragmented nucleic acids was low, it did 
not show on the agarose gel. Peak 2 is the isolated variant and likely corresponds to the apo-form 
of N-formyl methionine-cleaved ProCA-3. This is confirmed by SDS-PAGE gel, agarose gel, 
and mass spectrometry data (Figure 3.15, Figure 3.16).  
 
Figure 3.16. Mass spectrometry results of peaks 2 and 3 from the modified purification protocol. 
64 
 
Peaks 3, 4, and 5 are believed to be the holo-forms of methionine-cleaved ProCA-3 agents. SDS-
PAGE gel, agarose gel, and mass spectrometry data confirms the speculations of peak 3 
identification (Figure 3.15, Figure 3.16). Summarizing the results, the modified FPLC program 
yields a significant improvement in the overall yield of protein to a high degree of purity 
compared to the old methodology (Table 3.1). 
 
 
Figure 3.17. ProCA-30 Purification. (A) SDS-Page results of purification process. (B) FPLC 
chromatogram depicting isolation of target variant. 
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Figure 3.18. ProCA-31 Purification. (A) SDS-Page results of purification process. (B) FPLC 
chromatogram depicting isolation of target variant. (C) Relevant SDS Page results from FPLC 
separation. 
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Figure 3.19. ProCA-32 Purification. (A) SDS-Page results of purification process. (B) FPLC 
chromatogram depicting isolation of target variant and relevant SDS Page results from FPLC 
separation. 
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Figure 3.20. ProCA-33 Purification. (A) SDS-Page results of purification process. (B) FPLC 
chromatogram depicting isolation of target variant and relevant SDS Page results from FPLC 
separation. 
 
3.4. Final Yield 
Summarizing the aforementioned results of his chapter, the unrevised purification 
protocol closely resembles that of the current protocol. However, there were a few minor 
changes made that have drastically increased the purification yield. Incorporating the use of an 
optimal streptomycin sulfate concentration and modifying the FPLC salt gradient for separation, 
the yields of all members of Class ProCA-3 agents have increased nearly four to six times 
compared to the old methods with the exception of ProCA-33. Figures 3.21 and 3.22 further 
confirm the purity of contrast agent isolated. The UV spectra obtained are closely related to that 
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of the published expected spectra (see section 2.3). The yield of ProCA-33 was 39.41 mg and did 
not significantly increase compared to the implementation of the old purification protocol due to 
the inefficiency of the contrast agent binding to the Q-column. This is evidenced by the low 
resolution observed between the first two peaks in the FPLC chromatogram (Figure 3.15). This 
inefficacy is related to insufficient cleaning of the column and was due to human error.  
 
 
Figure 3.21. Maldi-TOF results confirming identity and purity of isolated members of Class 
ProCA-3 agents. 
 
 
Figure 3.22. Final UV absorbance spectra of class ProCA-3 agents. 
 
 
 
Table 3.1. ProCA-3 Purification Yields 
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ProCA-3  ProCA-30  ProCA-31  ProCA-32  ProCA-33  
Old Yield from 
2L LB media  
31.70 mg  37.50 mg  32.60 mg  41.50 mg  
New Yield from 
1L LB media  
109.12 mg  76.16 mg  60.21 mg 39.41 mg*  
*Due to human error, there was no significant increase in yield due to loss of protein during the 
FPLC injection stage. 
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4. CONFORMATIONAL ANALYSIS AND METAL STUDIES 
4.1. Background 
 It is of crucial importance that the structural integrity of the designed protein-based 
contrast agents of Class ProCA-3 maintains the native structure of parvalbumin, the scaffold 
protein. Maintenance of the characteristic alpha-helical structure allows one to draw the 
conclusion that the introduction of mutations into the skeletal structure does not significantly 
alter or perturb the proteins secondary structure, providing insight into their relative stabilities. 
Figure 4.1 depicts the published Far-UV spectrum of parvalbumin in the presence and absence of 
calcium. 
 
Figure 4.1.Published Far-UV spectrum of wildtype parvalbumin; Dashed line, metal-free form; 
solid line, Ca2+ loaded form [39]. 
 
Using circular dichroism to measure the Far-UV region absorptions, one is able to detect 
changes in secondary structure alone. It is important to note here that this technique does not 
allow one to draw conclusions about the intrinsic stability of the gadolinium binding site as a 
result of the introduced mutations in ProCA-31, ProCA-32, or ProCA-33. Furthermore, 
measuring the optical absorptions in the Far-UV CD region does not provide any indication of 
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potential changes in the globular or tertiary structure of the designed agents. To detect tertiary 
structural changes of the agents, the Near-UV spectrum, instead of the Far-UV region, must be 
examined using circular dichroism. However, for the purposes of this thesis, only the Far-UV 
CD region was observed. 
Not only is the maintenance of the secondary structure following the introduction of 
mutations important, but it is also of crucial importance to investigate the effects of increasing 
concentrations of physiological metal ions and high salt on the stability of the structure. For the 
purposes of this discussion, the effects of magnesium, calcium, gadolinium, and terbium will be 
examined. 
4.2. Magnesium-Induced Structural Effects 
Magnesium is a divalent metal that plays a major role in a number of biological 
processes. Under normal physiological conditions, the extracellular concentration of magnesium 
is 1-2mM. Native parvalbumin acts as a cytosolic buffering protein, respectively binding both 
calcium and magnesium, on the orders of 10-9M and 10-6M [25]. Therefore, at a fixed 6µM 
concentration of protein, the spectral changes associated with the addition of magnesium 
chloride to each contrast agent of Class ProCA-3 was observed at a 1:1 protein to Mg2+ 
concentration ratio, 1:2 protein to Mg2+ concentration ratio, 1mM Mg2+ , and an excessive 
amount of 5mM Mg2+. The metal-induced structural changes were observed under both low and 
high salt conditions. A major assumption drawn for these experiments is that the background 
metals and EDTA from purification present in the buffer system are below the micromolar range. 
However, this must be further verified. Nevertheless, some conclusions can be drawn. 
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4.2.1. ProCA-30 
ProCA-30 secondary structure changes under varying concentrations of magnesium were 
observed. At low salt concentrations, the protein maintains its native α-helical character with 
slight decreases in its helicity for the holo forms (Figure 4.2). Under high salt conditions, the 
reverse is true up to 1mM additional magnesium. At 5mM calcium, the helicity decreases. Here, 
it’s safe to assume that the presence of high salt helps to stabilize ProCA-30 up to 1mM 
magnesium. As will be later explained, more pronounced spectral differences are primarily seen 
between the low and high salt forms of the protein in the presence of calcium. 
 
 
Figure 4.2. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to magnesium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 100mM NaCl was used. 
 
4.2.2. ProCA-31 
ProCA-31 yields characteristic alpha-helix wavelength absorbencies at 209 nm and 222 
nm in the absence of additional added metals and in the presence of increasing concentration of 
magnesium under both low and high salt conditions (Figure 4.3). Thus the introduction of a 
F103W mutation does not significantly alter the secondary structure of the protein. For varying 
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ratios of magnesium, like ProCA-30, ProCA-31 decreases in helical character as the 
concentration of added magnesium increases under low salt conditions. The same can be said for 
high salt conditions, though more pronounced spectral differences were noted. Here, the 
presence of high salt has little effect on the stability of ProCA-31 in the presence of magnesium.  
 
 
Figure 4.3. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to magnesium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.2.3. ProCA-32 
Under the subjection to circularly polarized light, the Far-UV CD spectrum of 6µM 
ProCA-32 yields characteristic alpha-helix wavelength absorbencies at 209 nm and 222 nm in 
the presence of increasing concentrations of magnesium (Figure 4.4). This indicates that the 
mutation does not significantly alter the secondary structure of the protein. The helical content of 
the protein appears to slightly increase in the presence of magnesium under low salt conditions, 
implying enhanced stability. There are little notable spectral differences with increasing 
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concentration of magnesium under high salt conditions, indicating that ProCA-32 is fairly stable 
under comparable extracellular conditions.  
 
Figure 4.4. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to magnesium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.2.4. ProCA-33  
It is unclear whether the introduction of an aspartic acid in place of glutamic acid at 
position 60 located in the CD site and a tryptophan in lieu of phenylalanine at position 103 
located just outside of the EF site will significantly alter the secondary structure of the native 
skeletal design of the contrast agent. Furthermore, we are not certain of the metal-induced 
structural effects of this contrast agent. For varying concentrations of magnesium in a low salt 
buffer, ProCA-33 helical content is enhanced with increasing concentrations of magnesium 
(Figure 4.5A). With the exception of a slight decrease in helicity at 5mM magnesium, the helical 
content under high salt conditions remains fairly consistent, indicating that high salt plays little 
role in secondary structure destabilization of ProCA-33 in the presence of magnesium (Figure 
4.5B). 
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Figure 4.5. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to magnesium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.3. Calcium-Induced Structural Effects 
Calcium ions are one of the most abundant minerals in the human body and is essential 
for living organisms, particularly in cell physiology [40-41]. Though its concentration is 104 to 
106-fold less than that of magnesium and potassium intracellulary, respectively, calcium is not 
only “an essential structural component in the biomineralization of teeth, bones, and shells but 
also a ‘second messenger’ that controls numerous cellular processes such cell division and 
growth, secretion, ion transport, and muscle contraction through calcium-induced conformational 
change” [28]. More specifically, calcium-binding proteins with varying affinities for this metal 
mediate and regulate both extracellular and intracellular calcium-dependent functions [28]. 
Because their metal selectivity over other metal ions is closely related to many physiological 
processes and diseases, understanding the key factors in their selectivity and conformational 
change allows for a more in depth analysis of calcium signaling [28, 42]. 
76 
 
4.3.1. ProCA-30 
Pronounced spectral differences are primarily seen between the low and high salt forms 
of the protein in the presence of calcium (Figure 4.6). Under low salt conditions, ProCA-30 is 
destabilized as the concentration of calcium increases. Under high salt conditions, there are little 
notable differences with increasing concentrations of calcium with the exception of a decrease in 
helicity at 5mM calcium. Here, one can draw the conclusion that the presence of salt does little 
to perturb the structure up to 1mM calcium.  
 
Figure 4.6. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to calcium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.3.2. ProCA-31 
Because the alpha-helical structure is maintained, one can assume that the introduction of 
a F103W mutation just outside of the EF binding site does not significantly perturb the 
secondary structure of the protein (Figure 4.7). For varying ratios of calcium, more pronounced 
spectral changes between the different ratios of magnesium predominately occur under low salt 
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conditions (Figure 4.7). Under high salt conditions, there are little notable changes in the helical 
content, indicating that the ProCA-31 is stable under applicable in vivo salt concentrations. 
 
Figure 4.7. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to calcium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.3.3. ProCA-32 
The alpha-helical fold of ProCA-32 is maintained with introduction of a S56D mutation 
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter 
the secondary structure of the protein (Figure 4.8). In the presence of varying metal ratios in the 
absence of EGTA treatment at low and high salt concentrations, the protein maintains its native 
α-helical character (Figure 4.8). For varying ratios of calcium under both low and high salt 
conditions, ProCA-32 increases in helical character for all ratios and concentrations of metal 
added. Thus, ProCA-32 is a stable variant and the presence of high salt does little to destabilize 
the secondary structure. 
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Figure 4.8. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to calcium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.3.4. ProCA-33 
The alpha-helical fold of ProCA-33 is maintained with introduction of an E60D mutation 
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter 
the secondary structure of the protein. In the presence of varying metal ratios in the absence of 
EGTA treatment at low and high salt concentrations, the protein maintains its native α-helical 
character (Figure 4.9). For varying ratios of calcium, dominant spectral changes are more visible 
under low salt conditions. The helical content increases for all concentrations of added calcium 
under low salt while there are little to no spectral changes under high salt conditions. Like the 
aforementioned members of Class ProCA-3 in the presence of calcium, the presence of high salt 
does little to destabilize the secondary structure of the designed contrast agents. 
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Figure 4.9. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to calcium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.4. Gadolinium-Induced Structural Effects 
 Gadolinium is a paramagnetic metal whose local magnetic field perturbs the relaxation of 
water protons located on its surface. Once again, the members of Class ProCA-3 are expected to 
bind gadolinium in a 1 to 2 fashion. Here, we want to observe how the binding of gadolinium 
affects the secondary structure of the protein. 
4.4.1. ProCA-30 
Under both low and high salt conditions, the helical content of ProCA-30 appears to 
decrease for all added concentrations of gadolinium (Figure 4.10). This indicates that gadolinium 
is able to competitively displace “background metals” from the CD and EF binding sites, even at 
low concentrations of 6µM (1 to 1) and 12µM (1 to 2) gadolinium. However, this also indicates 
that gadolinium slightly destabilizes the secondary structure of ProCA-30 under both low and 
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high salt conditions. The presence of a high concentration of salt does little to perturb the 
structural changes associated with gadolinium-binding. 
 
Figure 4.10. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to gadolinium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.4.2. ProCA-31 
Because the native alpha-helical structure is maintained, it appears that the F103W 
mutation does not significantly alter the secondary structure of ProCA-31. For various added 
concentrations of gadolinium, ProCA-31 is destabilized because the helical character decreases 
for all ratios and concentrations (Figure 4.11). More pronounced spectral differences are 
associated with low levels of salt. There were only minor decreases in the helical content as 
increasing concentrations of gadolinium was added under high salt conditions. Thus, one can 
assert that the presence of high salt plays a nominal role in stabilizing the structure compared to 
low salt conditions. Nevertheless, as one can infer from Figure 4.11, the native structure of the 
ProCA-31 is maintained in the presence of gadolinium. 
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Figure 4.11. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to gadolinium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.4.3. ProCA-32 
The alpha-helical fold of ProCA-32 is maintained with introduction of a S56D mutation 
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter 
the secondary structure of the protein (Figure 4.12). For varying ratios of gadolinium, the helical 
character increases for almost all ratios and concentrations of added metal under both low and 
high salt conditions (Figure 4.12). Slightly less spectral differences were noted under high salt 
conditions, indicating that the presence of 100mM NaCl marginally enhances ProCA-32 
stability. Nevertheless, the ProCA-32 alpha-helical content retains the native structure in the 
presence of gadolinium. 
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Figure 4.12. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to gadolinium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.4.4. ProCA-33 
The alpha-helical fold of ProCA-33 is maintained with introduction of an E60D mutation 
in the CD site of wildtype parvalbumin (Figure 4.13). In the presence of varying gadolinium 
ratios in the absence of EGTA treatment at low and high salt concentrations, the protein 
maintains its native α-helical character (Figure 4.13). For varying ratios of gadolinium, the 
helical content increases for all ratios and concentrations under low salt conditions. Minimal 
spectral changes were observed under high salt conditions indicating that the presence of salt 
ions help to stabilize the secondary structure of ProCA-33. 
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Figure 4.13. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to gadolinium 
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 
7.4 (100 mM NaCl) was used. 
 
4.5. Terbium-Induced Structural Effects 
 Terbium is a trivalent metal ion used in fluorescent spectroscopy studies to probe the 
intrinsic properties of metal binding sites within biomolecules. Studies of this sort can provide 
information concerning the stability of the metal binding site and also contribute to quantifying 
the binding affinity of a biomolecule to a metal. Although these experiments were not discussed 
in this thesis, they will be performed in the near future. Thus, it was of importance to examine 
the secondary structural changes associated with increasing concentration of this metal. 
4.5.1. ProCA-30 
ProCA-30 maintains an alpha-helical structure like that of wildtype parvalbumin. More 
specifically, the structure is maintained with increasing concentrations of terbium (Figure 4.14). 
The spectral differences associated with the low salt spectrum were slightly greater than that of 
the high salt spectrum. Terbium appears to slightly destabilize the secondary structure of ProCA-
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30 under both low and to a nearly negligible degree of high salt conditions. Nevertheless, the 
native structure is maintained as the concentration of terbium increases. 
 
Figure 4.14. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to terbium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.5.2. ProCA-31 
As mentioned previously, the effects of F103W mutation on the fold of the protein are 
minor (Figure 4.15). For increasing ratios of terbium, the helical character decreases for all ratios 
and concentrations. Like ProCA-30, there are nominal spectral differences associated with 
increasing concentrations of terbium under high salt conditions compared to low salt conditions. 
Although the helicity is destabilized under both conditions, high salt helps to counter this 
destabilization. Still, one can conclude that the secondary structure is maintained in the presence 
of terbium at the tested concentrations.  
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Figure 4.15. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to terbium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.5.3. ProCA-32 
Once again, the alpha-helical fold of ProCA-32 is maintained with introduction of a 
S56D mutation in the CD site of wildtype parvalbumin, indicating that the mutation does not 
significantly alter the secondary structure of the protein (Figure 4.16). For varying ratios of 
terbium, the helical character increases for concentrations up to 5mM terbium under low and 
high salt conditions. Thus, though terbium appears to increase the stability of ProCA-32, salt 
plays little role in affecting the stabilization. 
 
86 
 
 
Figure 4.16. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to terbium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
  
4.5.4. ProCA-33 
It has been well established that the alpha-helical fold of ProCA-33 is maintained with 
introduction of an E60D mutation in the CD site of wildtype parvalbumin (Figure 4.17). In the 
presence of increasing ratios of terbium in the absence of EGTA treatment at low and high salt 
concentrations, the protein maintains its native α-helical character (Figure 4.17). For varying 
ratios of terbium, the helical content increases for all ratios and concentrations under low salt 
conditions. Only minor spectral changes are associated with high salt conditions indicating that 
the presence of high salt helps to stabilize the secondary structure of the protein in the presence 
of increasing concentrations of terbium. 
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Figure 4.17. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to terbium ratios. 
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4 
(100 mM NaCl) was used. 
 
4.6. Summary of Metal-Dependent Secondary Structural Changes 
It has been established that ProCA-30 maintains its native secondary structure following 
bacterial overexpression and purification. This is also confirmed by published CD spectra of 
ProCA-30 [39]. It was then investigated how the secondary structure of ProCA-31, ProCA-32, 
and ProCA-33 changed under extremely high concentrations of varying metals (Figure 4.18-
4.20). 
 
  .  
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Figure 4.18. CD Spectrum of 6 µM ProCA-31 in the Presence of 5mM Metals. (A) In the 
presence of 5mM EGTA. (B) No EGTA treatment. 
 
 
Figure 4.19. CD Spectrum of 6 µM ProCA-32 in the Presence of 5mM Metals. (A) In the 
presence of 5mM EGTA. (B) No EGTA treatment. 
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Figure 4.20. CD Spectrum of 6 µM ProCA-33 in the Presence of 5mM Metals in the absence of 
EGTA. 
 
In the presence of 5mM EGTA and 5mM Tb3+ or Gd3+, the α-helical content of ProCA-
31 and ProCA-32 decreases in helicity and the spectrum shifts to a random coil (Figures 4.18-
4.20). No protein precipitation was noted. There are a number of possible explanations for the 
random coil formation noted for ProCA-31 and ProCA-32 the presence of 5mM gadolinium and 
terbium The first may be due to nonspecific binding of metal ions to various sites on the protein, 
disrupting the hydrogen bonds helping to maintain the protein’s native structure. The second 
explanation may be due to pH effects induced as EGTA binds the metal ions (Table 4.1). For 
every EGTA that binds a metal ion, four protons are released, decreasing the pH of the system. 
Though the CD samples are immersed in a buffering system of 10mM Tris/HCl, the 10mM 
concentration of Tris/HCl may not be sufficient to balance or maintain the pH environment of 
the sample at pH 7.4. If the conformation of the protein changes from an alpha helix to a random 
coil at 5mM concentration of these two metals in the absence of EGTA, one can safely assume 
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that the induction of conformational change was due to nonspecific binding of the metal ion to 
the protein instead of due to pH changes. This in fact proved to be the case. 
At 5mM Mg2+, Ca2+, Tb3+, or Gd3+ in the absence of EGTA, the ProCA-31, ProCA-32, 
and ProCA-33 maintain the native structure. The helical content of ProCA-31 appears to 
decrease in the presence of calcium and increase in the presence of magnesium. Possible 
explanations for these phenomena are not well understood. One would anticipate that the helicity 
of ProCA-31 would increase in the presence of calcium since it has a much stronger binding 
affinity to this particular metal than magnesium. The helical content of ProCA-33 appears to 
increase in the presence of all tested metals at 5mM concentration and decrease in the presence 
of EGTA. One can draw the presumption that the presence of the tested metals enhances the 
structural stability of ProCA-33. 
Table 4.1. pH Effects Observed Before and After the Addition of EGTA. 
 
 ProCA-30 ProCA-31 ProCA-32 ProCA-33 
 10mM 
metal 
10mM 
metal 
and 
5mM 
EGTA 
10mM 
metal 
10mM 
metal 
and 
5mM 
EGTA
10mM 
metal 
10mM 
metal 
and 
5mM 
EGTA
10mM 
metal 
10mM 
metal 
and 
5mM 
EGTA 
Mg2+ 7.51 6.77 7.50 6.80 7.49 6.86 7.46 6.85 
Ca2+ 7.36 4.53 7.39 4.39 7.41 4.42 7.42 4.42 
Tb3+ 6.49 2.23 6.65 2.29 6.60 2.33 6.63 2.27 
Gd3+ 6.70 2.32 6.54 2.30 6.78 2.35 6.73 2.35 
 
 In the presence of varying metal ratios in the absence of EGTA treatment at low and high 
salt concentrations, the proteins maintain their native α-helical character. Pronounced spectral 
differences are primarily seen between the low and high salt forms of the protein. Significant 
structural changes were predominately noted at concentration of 1mM metal and higher. It’s 
reasonable to assume that the background concentration or “contamination” of metals is likely 
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above 6µM. Therefore, although the buffer signals were subtracted from the metal-contrast agent 
signals, the added magnesium, calcium, gadolinium, and terbium for 1:1 and 1:2 protein to metal 
ratios may not be sufficient for displacing resting calcium or magnesium in the CD and EF 
binding sites. Thus, only minor spectral changes were noted.  
In summary, one can conclude that all members of Class ProCA-3 retained the native alpha-
helical fold. The introduction of mutations into the skeletal design of Class ProCA-3 did not 
significantly alter the secondary structure of the protein and the presence of high salt did little to 
destabilize the structure. Special attention should be paid for significant pH changes following 
the addition of high concentration of metals in the presence of EDTA. Furthermore, the members 
of this class exhibit strong secondary structure stability against high concentrations of Mg2+, 
Ca2+, Tb3+, or Gd3+, allowing one to infer that an excellent scaffold structure chosen for contrast 
agent design.   
4.7. Determined Metal Binding Affinities of Class ProCA-3  
For the purposes of presenting a more comprehensive study of the members of Class 
ProCA-3 agents, the binding affinity of each agent, with the exception of ProCA-30, to calcium, 
terbium, and gadolinium was determined by senior researcher David Xue. Using a competitive 
metal titration aided by fluorescence spectroscopy, 20µM of protein in 100mM Tris/HCl 100mM 
NaCl chelex pH 7.4 was initially saturated with terbium and the binding affinity (kD) of the 
protein to terbium was calculated using the Hill equation. Then, terbium was competitively 
competed out by increasing concentrations of either calcium or gadolinium. Using the equation 
in Figure 4.21 below, the binding affinity of the protein to either calcium or gadolinium was 
approximated. ProCA-32 was found to have the highest affinity for gadolinium compared to the 
other members studied. The remaining kD values for each agent are listed in Figure 4.22.  
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Figure 4.21. Class ProCA-3 metal binding ability. 
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5. RELAXIVITY MEASURES 
5.1. Introduction 
As discussed in chapter 1 (section 1.1.2), relaxivity is a quantitative term used to reflect 
the intrinsic contrast capability of a contrast agent per gadolinium ion. The measured relaxivity 
is governed by the sample prep conditions and the relaxation properties of the agent discussed in 
chapter 1. Thus, it is important to determine the conditions for sample preparation. This chapter 
describes studies on the required sample volume, incubation time frame, and metal equilibration 
for accurate in vitro relaxation time measurements. Additionally, two different protocols for 
measuring relaxivity were implemented to determine how the relaxivity of the contrast agents 
change when bound to one gadolinium versus two and to accurately determine the maximum 
relaxivity and binding mode. The effect of salt on the measured relaxivity of the members of 
Class ProCA-3 was also investigated 
The conditions for measuring relaxivity as they relate to the effect of sample volumetric 
changes, effect of sample incubation time, and extent of time required for metal equilibration 
were first determined. To determine the effect an increase in volume has on the relaxation times, 
the relaxation times of low concentrations of free gadolinium at 200µL and 400µL volumes were 
measured. Figure 5.1A illustrates that the differences in T1 relaxation times are within the range 
of fitting error (with the exception of 10µM gadolinium) while more notable differences were 
observed in T2 relaxation times. However, these results are not reliable, as they are within the 
range of residual background metal concentrations as later explained in the details outlining 
optimization of the fixed gadolinium protocol. Because less pronounced changes were noted in 
T1, it was decided to continue using 200µL volumes for relaxivity measurements.  
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To determine the effects of different incubation times at 37˚C on relaxation times, a 
sample of 50µM ProCA-32 and 100µM Gd3+ was arbitrarily chosen to note changes for 5 
minutes, 4 hours, and overnight incubation. Figure 5.1B yields that there are only minor 
variances in the relaxation times as a function of incubation time. SDS-PAGE analysis indicates 
that the protein is stable over the measured incubation times. However, it is important to note the 
inconsistency in the density of the bands for lanes 1 and 2 of the gel in Figure 5.1C. This was 
likely due to a sample loading human error. Nevertheless, it appears that the length of incubation 
up to overnight conditions at 37˚C has no significant effect on the relaxation times.  
To determine the extent of metal equilibration time necessary to measure accurate 
relaxation times, a ProCA-31 relaxivity sample, pseudo-form of ProCA-30, was chosen under 
the presumption that the contrast agent bearing the weakest binding affinity to gadolinium 
(found by Senior PhD researcher David Xue) would require the longest amount of time to bind 
the metal compared to ProCA-32 and ProCA-33. Therefore, ProCA-31 was prepared in a 1 to 2 
ratio (50µM ProCA-31 and 100µM gadolinium) and the concentration of free metal following 30 
minutes, 3 hours, and overnight equilibration was measured using a weak calcium-binding dye 
Rhodamine-5N (Figure 5.1C). Theoretically, the optimal equilibration time will have the lowest 
concentration of free metal. Of the observed time points, it was found that overnight 
equilibration yielded the lowest concentration of free metals. Therefore, it was determined that 
the relaxivity samples for future measure (fixed gadolinium experiments) would be equilibrated 
overnight.  
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5.1. Optimizing Relaxivity Sample Prep Conditions. (A) Volumetric observations. (B) 
Incubation time assay. (C) Metal equilibration schemes.     
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5.2. Determining Relaxivity Using Two Different Protocols 
The parameter relaxivity is directly proportion to the amount of signal intensity visualized in 
an MR image. Therefore, the higher the relaxivity, the greater the signal intensity and thus a 
more improved differentiated image of normal versus diseased tissues. Here, we use two 
different methods to determine an accurate relaxivity value. The traditional method for 
measuring relaxivity is well established. It is commonly implemented to measure the relaxivity 
of commercially available contrast agents. Using this method, the relaxation times of different 
protein-gadolinium samples prepared at a fixed ratio were measured. The slope of the linear 
plots represents the relaxivity of the sample at the fixed ratio. The second method used involves 
fixing the gadolinium concentration and increasing the protein concentration. It was originally 
developed to design a novel way of using a relaxometer to measure the binding affinity of a 
protein to gadolinium. Details into extrapolating the dissociation constant from the relaxivity 
data are not discussed here. This newly developed method also allows one to eliminate effects on 
relaxivity associated with the interference of non-specific binding of gadolinium with the 
contrast agents at significantly high concentrations of gadolinium. Using this method, one can 
obtain the maximum relaxivity of the protein-gadolinium complex by averaging the relaxivity of 
ratios occurring in the plateau portion of the curve formed during the experiment. Furthermore, 
this method allows one to gain insight into the binding stoichiometry of developed contrast 
agents. The latter two uses for the newly developed protocol are discussed in this thesis. 
 
5.3. Traditional Methods for Measurement 
Class ProCA-3 Agents are multi-binding site contrast agents that can selectively bind a 
maximum of two metal ions, one in their CD and EF sites respectively. We assume that there is 
little to no nonspecific binding of gadolinium at the experimental concentrations used, as we do 
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not exceed a 1:2 protein to gadolinium ratio in our sample preparative methods. However, this 
must be further investigated. Though secondary structural analysis was performed, it is unclear 
at this time how increasing concentrations of metal affect the tertiary structure of the agents. 
Also, it has not been determined whether decreasing the ratio of protein to gadolinium in 
solution will lead to significant global structural changes. This also must be further investigated. 
Nevertheless, it has been proposed that increasing the number of gadolinium binding sites 
shortens the longitudinal and transverse relaxation times, thus increasing the relaxivity. For this 
reason, the relaxivity for the 1:2 ratio is expected to be higher than that of the 1:1 ratio. 
However, this phenomenon is not observed under low or high salt conditions (see section 2.6 for 
experimental details).  
Using the traditional protocol mentioned in chapter 2 (section 2.6), the relaxation times T1 
and T2 were measured at fixed protein to gadolinium ratios of 1:1 and 1:2 under low and high 
salt conditions. The concentration (µM) ratios of protein to gadolinium for the 1:1 experiment 
were as follows: 10:10, 20:20, 30:30, 40:40, and 50:50. The concentration (µM) ratios of protein 
to gadolinium for the 1:2 experiment were as follows: 10:20, 20:40, 30:60, 40:80, and 50:100. 
This concentration dependence assay allows for one to calculate the in vitro relaxivity as a 
function of protein concentration (or of gadolinium concentration for 1:1) by taking the slope of 
the line formed by the series of fixed protein to gadolinium ratios. To calculate the relaxivity of 
the 1:2 experiment as a function of gadolinium concentration, the slope of the line must be 
halved. Otherwise, the relaxivity as a function of the protein concentration for the 1:2 
experiments can be taken from the slope of the line. Tables 5.1 and 5.2 reveal the calculated 
relaxivity values per gadolinium ion for the developed contrast agents discussed in this thesis. 
Table 5.1. In vitro relaxivity of designed contrast agents under low salt conditions. 
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 1:1 1:2 
Developed 
Contrast Agent 
R1 (mM-1 s-1) R2 (mM-1 s-1) R1 (mM-1 s-1) R2 (mM-1 s-1) 
Gd DTPA 3.8 4.5 3.8 4.5 
ProCA-30 28.13 ± 1 36.75 ± 1 27.20 ± 1 35.42 ± 2 
ProCA-31 28.10 ± 3 36.25 ± 4 31.87 ± 4 41.60 ± 4 
ProCA-32 7.64 ± 0.2 10.04 ± 1 20.40 ± 6 26.64 ± 7 
ProCA-33 5.07 ± 0.1 5.49 ± 1 8.08 ± 1 10.43 ± 1 
The samples were prepared in 10mM Tris/HCl chelex pH 7.44. 
 
Table 5.2. In vitro relaxivity of designed contrast agents under high salt conditions. 
 
 1:1 1:2 
Developed 
Contrast Agent 
R1 (mM-1 s-1) R2 (mM-1 s-1) R1 (mM-1 s-1) R2 (mM-1 s-1) 
Gd DTPA 3.8 4.5 3.8 4.5 
ProCA-30 27.33 ± 2 36.11 ± 2 28.32 ± 1 33.36 ± 6 
ProCA-31 31.38 ± 0.3 40.86 ± 1 28.32 ± 2 36.52 ± 7 
ProCA-32 9.46 ± 0.3 12.17 ± 0.3 21.07 ± 1 27.52 ± 1 
ProCA-33 5.05 ± 0.2 5.55 ± 1 7.82 ± 1 8.62 ± 2 
The samples were prepared in 10mM Tris/HCl chelex 100mM NaCl pH 7.44. 
 
As one can observe, the T1 and T2 times for ProCA-30 shorten as the protein to metal ratio 
increases for both low and high salt conditions (Figure 5.2).  
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Figure 5.2. ProCA-30 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology. 
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions. 
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The average R1 and R2 values for ProCA-30 under low salt conditions for a 1:1 binding ratio 
are 28.13 ± 1 mM-1 s-1 and 36.75 ± 1 mM-1s-1, respectively while for a 1:2 binding ratio, the 
values are 27.20 ± 1 mM-1 s-1 and 35.42 ± 2 mM-1 s-1, respectively. Similarly, the average R1 and 
R2 values or ProCA-30 under high salt conditions for a 1:1 binding ratio are 27.33 ± 2 mM-1 s-1 
and 36.11 ± 2 mM-1 s-1, respectively while for a 1:2 binding ratio, the average relaxivities are 
28.32 mM-1 s-1 ± 1 and 33.36 ± 6 mM-1 s-1, R1 and R2 respectively (Figure 5.3).  
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Figure 5.3. ProCA-30 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots 
under low salt conditions. (B) Linear plots under high salt conditions. 
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There were little differences between the 1:1 and 1:2 ratios under both low and high salt 
conditions, indicating that the presence of high salt does little to significantly alter the relaxivity 
values. Furthermore, the saturation of both binding sites in ProCA-30 does not significantly 
enhance the relaxivity. Correlating this with the CD data in chapter 4 (section 4.4.1), although 
increasing concentrations of gadolinium appears to destabilize the secondary structure under 
both low and high salt conditions, the presence of high salt does little to disturb metal-dependent 
structural changes (Figure 4.10). Additionally, the nominal CD spectral differences associated 
with a 1 to 1 and 1 to 2 binding ratio are consistent with the little variance in relaxivity values for 
these ratios under both salt conditions. Moreover, these values yield exciting results, showing 
that the relaxivity 1 and 2 values of ProCA-30 are significantly higher than those of commercial 
Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1, respectively. 
Like that of ProCA-30, the T1 and T2 times of ProCA-31 shorten as the protein to metal ratio 
increases for both low and high salt conditions (Figure 5.4).  
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Figure 5.4. ProCA-31 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology. 
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions. 
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The average R1 and R2 values of ProCA-31 under low salt conditions for a 1:1 binding ratio 
are 28.10 ± 3 mM-1 s-1 and 36.32 ± 4 mM-1s-1, respectively while for a 1:2 binding ratio, the 
values are 31.87 ± 4 mM-1 s-1 and 41.60 ± 4 mM-1 s-1, respectively. Under high salt conditions 
for a 1:1 binding ratio, the average R1 and R2 values are 31.38 ± 0.3 mM-1 s-1 and 40.86 ± 1 mM-
1 s1, respectively while for a 1:2 binding ratio under high salt conditions, the averaged R1 and R2 
values are 28.32 ± 2 mM-1 s-1 and 36.52 ± 7 mM-1 s-1, respectively (Figure 5.5). Like ProCA-30, 
the presence of high salt does not significantly alter the relaxation times. Correlating this with 
the CD data in chapter 4 (section 4.4.2), although increasing concentrations of gadolinium 
appears to destabilize ProCA-31 secondary structure under low salt conditions, the presence of 
high salt helps stabilize the metal-dependent structural changes (Figure 4.11). Additionally, the 
CD spectral differences associated with a 1 to 1 and 1 to 2 binding ratio are inconsistent with the 
relaxivity values under low salt conditions and consistent with the little variance in relaxivity 
values for these ratios under high salt conditions. It is apparent that the structural destabilization 
under low salt conditions is not significant enough to alter the relaxivity values. 
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 Figure 5.5. ProCA-31 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear 
plots under low salt conditions. (B) Linear plots under high salt conditions. 
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It appears that ProCA-30 and ProCA-31 have nearly identical relaxivity values. If one 
recalls, these two agents represent the control and pseudo-control agents for Class ProCA-3. It is 
apparent that the F103W mutation made just outside of the EF loop (ProCA-31) of the skeletal 
structure of the protein does little to perturb its intrinsic relaxation times. These results are 
exciting, as they not only reveal relaxivity 1 and 2 values significantly higher than those of 
commercial Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1, respectively, but also allow one to 
conclude that the introduction of a tryptophan residue at position 103 proves as an effective tool 
to potentially monitor the intrinsic fluorescence of Class ProCA-3 agents for future structural 
and metal-binding studies. A high salt environment only slightly lowers the relaxivity values for 
ProCA-31 as compared to low salt conditions. 
The relaxivity of ProCA-32 yields interesting results. As one can observe, the T1 and T2 
values shorten as the protein to metal ratio increases for both low and high salt conditions 
(Figure 5.6).  
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Figure 5.6. ProCA-32 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology. 
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions. 
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The average R1 and R2 values for ProCA-32 under low salt conditions for a 1:1 binding ratio 
are 7.64 ± 0.2 mM-1 s-1 and 10.04 ± 1 mM-1s-1, respectively while for a 1:2 binding ratio, the 
values are 20.40 ± 6 mM-1 s-1 and 26.64 ± 7 mM-1 s-1, respectively. The average R1 and R2 
values under high salt conditions for a 1:1 binding ratio are 9.46 ± 0.3 mM-1 s-1 and 12.17 ± 0.3 
mM-1 s-1, respectively while for a 1:2 binding ratio, the values are 21.07 ± 1 mM-1 s-1 and 27.52 ± 
1 mM-1 s-1, respectively (Figure 5.7).  
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Figure 5.7. ProCA-32 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots 
under low salt conditions. (B) Linear plots under high salt conditions. 
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 The 1 to 1 relaxivity values under low salt conditions are slightly lower than those under 
high salt conditions. However, the 1 to 2 binding ratios under both salt conditions are within the 
range of error. This indicates that high salt has a more positive effect on increasing the relaxivity 
at the 1 to 1 ratio versus the 1 to 2 ratio. As one can infer, the 1:2 ratios are nearly 2.5 times 
higher that of the 1:1 under both low and high salt conditions. Correlating this with the CD data 
in chapter 4 (section 4.4.3), increasing concentrations of gadolinium appears to stabilize ProCA-
32 secondary structure under both salt conditions. However, as with the 1 to 1 relaxivity 
samples, the presence of high salt helps better stabilize the metal-dependent structural changes 
(Figure 4.12). The lack of CD spectral differences associated with a 1 to 1 and 1 to 2 binding 
ratio under both salt conditions is inconsistent with the increase in relaxivity values for these 
ratios. It appears that the measured relaxation times of ProCA-31 are independent of metal-
induced changes in secondary structure.  
Previous binding studies of this class of agents have shown that ProCA-32 bears the highest 
binding affinity to gadolinium. Here, it appears that the introduction of an additional charged 
residue into the CD site of the contrast agent significantly improves the relaxivity of the contrast 
agent at a 1:2 ratio versus a 1:1 ratio. These results are exciting, revealing relaxivity 1 and 2 
values significantly higher than those of commercial Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1, 
respectively. The presence of high salt does little to significantly alter the relaxivity values. By 
design, the site-directed mutagenesis approach has improved the relaxivity of the agent 
following metal saturation. However, it’s important to note here that the relaxivity of ProCA-30 
and ProCA-31, void of CD or EF site mutations, maintain higher relaxivity values than that of 
ProCA-32. These results are not well understood. It’s possible that the introduction of an 
additional charged residue enhances dimerization of the agent in solution, hampering the 
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relaxivity or rather increasing the relaxation times measured. This negative effect could possibly 
be related to significantly slowing the rotational correlation time. 
Like ProCA-32, the relaxivity results for ProCA-33 yield unexpected values. Like the 
previously mentioned members of Class ProCA-3 agents, the T1 and T2 intensity values for 
ProCA-33 decrease as the protein to metal ratio decreases for both low and high salt conditions 
(Figure 5.8).  
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Figure 5.8. ProCA-33 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology. 
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions. 
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The average R1 and R2 values under low salt conditions for a 1:1 binding ratio are 5.065 ± 
0.1 mM-1 s-1 and 5.49 ± 1 mM-1 s-1, respectively while that for a 1:2 binding ratio are 8.08 ± 1 
mM-1 s-1 and 10.43 ± 1 mM-1 s-1, respectively. The average R1 and R2 values under high salt 
conditions for a 1:1 binding ratio are 5.05 ± 0.2 mM-1 s-1 and 5.55 ± 0.3 mM-1 s-1, respectively 
while that for a 1:2 binding ratio are 7.82 ± 1 mM-1 s-1 and 8.62 ± 1 mM-1 s-1, respectively 
(Figure 5.9).  
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Figure 5.9. ProCA-33 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots 
under low salt conditions. (B) Linear plots under high salt conditions. 
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The presence of high salt does little to significantly alter the relaxivity values. Furthermore, 
the 1:2 ratios are only slightly higher than that of the 1:1 under both low and high salt conditions. 
Correlating this with the CD data in chapter 4 (section 4.4.4), increasing concentrations of 
gadolinium appears to stabilize ProCA-32 secondary structure under low salt conditions (Figure 
4.12). The presence of high salt appears to stabilize the metal-dependent structural changes 
(Figure 4.12). The lack of CD spectral differences associated with a 1 to 1 and 1 to 2 binding 
ratio under both salt conditions is consistent with the measured relaxivity values for these ratios.  
The ProCA-33 results do not reveal relaxivity 1 and 2 values significantly higher than those 
of commercial Gd-DTPA of 3.8 mM-1 s-1and 4.5 mM-1 s-1, respectively. It seems the introduction 
of a slightly shorter residue in the CD site of the skeletal design of the agent (E60D) may perturb 
the intrinsic properties of the CD gadolinium binding site and hamper the optimal effects 
associated with the rate of water exchange in the metal binding site. Hence, there are minimal 
changes in relaxivity associated with the saturation of the protein agent with two gadolinium ions 
versus one metal ion. Additionally, the low relaxivity values may also be due to the same 
dimerization phenomenon given as an explanation for ProCA-32’s lower relaxivity. The notably 
low relaxivity values for ProCA-33 compared to those of previously discussed members of Class 
ProCA-3 requires further investigation.  
In summary, it appears that the measured relaxivity values are not necessarily affected by 
metal-induced structural changes. ProCA-32 is the only member of Class ProCA-3 whose 
increase in relaxivity from the 1 to 1 to the 1 to 2 ratio under both salt conditions doesn’t 
correlate significant changes in the protein’s secondary structure. The remaining members yield 
positive correlations with the CD data between their consistent relaxivity values under both salt 
conditions at 1 to 1 and 1 to 2 ratios.  
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5.4. Measuring Relaxivity by Fixing [Gd3+] and Increasing Protein Concentration 
The primary goal of this experiment is multifaceted. Using different fixed concentrations 
of gadolinium (10, 50, or 100 µM) with increasing protein concentration, we are able to 
determine the optimal range for approximating the binding affinity of gadolinium to the protein 
used, the binding stoichiometry (that is whether the protein binds one, two, etc gadolinium ions), 
and the average relaxivity. It’s important to note here that for proteins with multiple binding 
sites, an assumption has been made that all the binding sites have equal binding affinities (based 
on published results of parvalbumin for example) and the data can thus be fit by a 1 to 1 
equation. This method is still in further development and therefore not mentioned in this 
protocol. Still, using the optimal fixed concentration of gadolinium and increasing the protein 
concentration, we can effectively determine the binding mode of the protein and approximate the 
maximum relaxivity 1 and 2 (R1 and R2) of the contrast agent used.  
 
5.4.1. Protocol Optimization Using ProCA-30 
To determine whether the protein to metal binding is truly at a 1:2 ratio, GdCl3 was fixed 
at varying concentrations and the concentration of protein was steadily increased. Figure 5.10 
depicts the change in relaxation times of ProCA-30 as the ratio of protein to gadolinium 
increases for fixed 10µM, 50µM, and 100µM gadolinium. 
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Figure 5.10. ProCA-30 T1 and T2 Signal Intensity Plots per fixed 10, 50, and 100µM Gd3+ 
concentration. 
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The protein concentration was then plotted as a function of the reciprocal T values to 
yield a hyperbolic curve. If the binding is 1:1, the curve will reach saturation at a protein 
concentration equal to that of the fixed Gd3+ concentration. If the binding is 1:2, the curve will 
reach saturation at a protein concentration equal to one-half of the fixed Gd3+ concentration 
(Figure 5.11). 
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Figure 5.11. Relaxivity curves of ProCA-33 at different fixed concentrations of Gd3+. (A) 
ProCA-30 at fixed 10µM [Gd3+]. (B) ProCA-30 at fixed 50µM [Gd3+]. (C) ProCA-30 at fixed 
100µM [Gd3+]. 
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At a fixed 10µM concentration of Gd3+, the curve reaches saturation at 10µM of protein 
concentration. It appears that the binding is 1:1 at this concentration. However, there are minimal 
changes in the relaxation times as the ratio of protein to gadolinium increases, indicating that the 
measured values have a fairly large range of error. Furthermore, it’s likely that this low fixed 
concentration of gadolinium is not ideal for determining the binding mode or relaxivity, as 
background metal contamination due to calcium or magnesium may significantly interfere with 
gadolinium binding to the designed metal binding site in the contrast agent. For example, if 
calcium background “contamination” is equal to or higher than that of fixed 10µM gadolinium, 
then at a 1:1 protein to gadolinium concentration ratio, the ratio of protein to gadolinium may be 
equal to that of protein to calcium. This implies that the binding sites of the contrast agent may 
be saturated with calcium and gadolinium and thus gadolinium cannot completely displace 
calcium from the binding site at such a low fixed concentration. Thus, the relaxivity of the 
contrast agent cannot be accurately measured. At fixed 50 and 100µM concentrations of Gd3+, 
the curves reach saturation at one-half of their respective fixed Gd3+ concentrations (Figure 5.11 
B-C). The change in relaxation times are much more pronounced as the ratio of protein to 
gadolinium increases when compared to that of a fixed 10µM concentration of Gd3+. From our 
experiments thus far, we have found that a fixed concentration of 100 µM gadolinium (and to a 
slightly lesser degree 50 µM) yields the most accurate range for measuring changes in relaxation 
times with increasing protein concentration at a fixed gadolinium value. Thus, this concentration 
range is optimal for determining the binding mode and average relaxivity of a contrast agent. 
 Both the fixed 50µM and 100µM concentrations of Gd3+ indicate that ProCA-30 binds 
Gd3+ in a 1:2 protein to gadolinium ratio and the possibility of nonspecific binding can be 
excluded from the potential alternative binding modes of the protein (Figure 5.11 B-C). The 
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average R1 and R2 for ProCA-30 were calculated to be 31 ± 2 mM-1 s-1 and 42 ± 2 mM-1 s-1, 
respectively. These values are nearly identical to those calculated from the traditional method 
(Table 5.2). 
5.4.2. ProCA-31 
 Using a fixed concentration of 100µM Gd3+, the signal intensity trends of relaxation time 
follow a similar pattern to that of ProCA-30 (Figure 5.12). The relaxation times shorten as the 
ratio of protein to gadolinium increases until the protein becomes fully saturated with 
gadolinium. 
 
Figure 5.12. ProCA-31 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM. 
 
The change in relaxation times reaches saturation at 50µM ProCA-31, indicating that the 
binding is 1:2. The average R1 and R2 values calculated from the saturated portion of the curve 
in are 42.87 ± 1 mM-1 s-1 and 55.75 ± 1 mM-1 s-1, respectively (Figure 5.13). Comparing these 
values to that of the 1:2 relaxivity values approximated by the traditional method, ProCA-31 has 
a higher relaxivity (Table 5.2). Furthermore, it maintains relaxivity values nearly ten times that 
of ProCA-30. The reasons behind this significant difference in R1 and R2 values are not well 
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understood. One could postulate that the addition of a tryptophan residue just outside of the EF 
gadolinium binding site changes the inner sphere water coordination, slowing the rate of water 
molecule exchange with the bulk solvent. As a result, the relaxation time is shortened and the 
relaxivity increases. Still, this must be further investigated.  
 
Figure 5.13. Relaxivity curves of ProCA-31 at a fixed 100µM concentration of Gd3+. 
 
5.4.3. ProCA-32 
Like ProCA-30 and ProCA-31, the relaxation times shorten as the ratio of protein to 
gadolinium increases until the protein reaches a 1:2 concentration ratio with gadolinium. 
However, as the ratio of protein to gadolinium begins to increase above this ratio, the relaxation 
times begin to steadily lengthen (Figure 5.14, Figure 5.15). Thus, the overall relaxivity 
calculated from the slope of the ratios above 1:2 yield a relaxivity value significantly lower than 
anticipated. Using a fixed concentration of 100µM Gd3+, the change in decreasing relaxation 
times peaks at 50µM ProCA-32, indicating that the binding is 1:2. The average R1 and R2 values 
calculated from the saturated portion of the curve in Figure 5.15 are 15.39 ± 0.4 mM-1 s-1 and 
123 
 
19.95 ± 1 mM-1 s-1, respectively. Comparing these values to that of the 1:2 relaxivity values 
approximated by the traditional methods, ProCA-32 has a lower relaxivity (Table 5.2).  
It is unclear why the curve rapidly drops at ratios higher than 1:2 (Figure 5.15). The 
reasons behind this observed phenomenon are not well understood. One possible explanation 
could be due to the heterogeneous nature of ProCA-32 gadolinium binding sites. The serine to 
aspartic acid mutation made at position 56 is identical to the serine to aspartic acid mutation 
made at position 55 of Michael Henzl’s studies of rat α- and β-parvalbumins neglecting our 
phenylalanine to tryptophan mutation added at position 103 outside of the EF loop (Henzl’s 
numbering of parvalbumin residues counts the first methionine cleaved as residue number one 
whereas our studies do not) [34]. Henzl’s studies report macroscopic stepwise calcium binding 
constants for the S55D mutation in buffer 0.025M Hepes 0.15M NaCl pH 7.4 at 25˚C, where K1 
(M-1) is 2.1 (0.2) x 108 and K2 (M-1) is 5.0 (0.2) x 107 [34]. Assuming that the properties of 
gadolinium binding are comparable to that of calcium binding due to their positive charge and 
comparable ionic radii, one can assume that this mutation maintains ten-fold differentiated metal 
binding sites. We assume here that the CD loop is the higher affinity metal binding site while the 
EF loop is the weaker metal binding site, as the ProCA-32 mutation yields a higher overall 
dissociation constants compared to the pseudo wildtype ProCA-31 (Figure 4.21) [34]. This 
provides an explanation for the attenuated increase in relaxation times above 50µM ProCA-32. 
At concentrations of 50µM and below, the relaxivity signal is predominantly due to saturation of 
both the weak (lower affinity EF site) and strong (higher affinity CD site) metal binding sites, as 
the protein concentration is significantly lower than that of the fixed gadolinium concentration of 
100. The slope of this portion of the curve yields the average relaxivity of ProCA-32 and excess 
free gadolinium. Above 50µM protein, the introduction of excess protein or unoccupied metal 
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binding sites “recruits” gadolinium ions to the stronger metal binding site, leaving the weaker 
metal binding sites unoccupied. Therefore, the increasing concentration of protein reduces the 
concentration of total saturated metal binding sites and relaxivity decreases. The slope of the 
curve above 50µM ProCA-32 corresponds to the relaxivity of the strong metal binding sites.    
 
Figure 5.14. ProCA-32 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM. 
 
 
 
Figure 5.15. Relaxivity curves of ProCA-32 at a fixed 100µM concentration of Gd3+. 
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5.4.4. ProCA-33 
The relaxation times of ProCA-33 shorten as the ratio of protein to gadolinium increases 
until the protein reaches a 1:3 concentration ratio with gadolinium (Figure 5.16, Figure 5.17). 
The relaxation times rapidly drop at the 1:2 ratio. Above the 1:2 ratio, the relaxation times begin 
to plateau. Because of this unexpected lengthening of relaxation times, the overall relaxivity 
calculated from the slope of the ratios above 1:2 yield a relaxivity value significantly lower than 
anticipated. Furthermore, using a fixed concentration of 100µM Gd3+, the change in decreasing 
relaxation times peaks at 38µM ProCA-33 indicating that the binding is 1:3. However, this 
phenomenon is not well understood. It’s possible that at this concentration ratio, the dimerization 
of the protein begins to occur. To further address the binding mode of ProCA-33, a reverse 
titration of the fixed gadolinium experiment was performed. ProCA-33 concentration was fixed 
at 50µM and increasing amounts of gadolinium was titrated into the system up to a 1 to 4 
ProCA-33: Gd3+ ratio (Figure 5.18). The sharp increase noted at the 100µM gadolinium indicates 
that the binding is 1:2. Thus, devoid potential dimerization effects, ProCA-33 binds two 
gadolinium ions. While the reverse titration method can provide more detailed information 
concerning the binding mode, it cannot accurately represent the average relaxivity of a contrast 
agent due to the variances in gadolinium concentration. Thus, the average R1 and R2 values 
calculated from the saturated portion of the curve in Figure 5.17 are 7.16 ± 0.7 mM-1 s-1 and 8.34 
± 1 mM-1 s-1, respectively. Comparing these values to that of the 1:2 relaxivity values 
approximated by the traditional methods, the values for ProCA-33 are nearly identical (Table 
5.2).  
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Figure 5.16. ProCA-33 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM. 
 
 
Figure 5.17. Relaxivity curves of ProCA-33 at a fixed 100µM concentration of Gd3+. 
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Figure 5.18. ProCA-33 reverse titration for binding mode determination. 
 
It was suggested that the sudden increase in relaxation times noted for ProCA-32 and 
ProCA-33 (Figures 5.15 and 5.17) was due to the presence of excess EDTA introduced into the 
system during the FPLC separation purification process. Theoretically, excess EDTA at 
comparable concentrations of contrast agent would competitively compete with the protein for 
gadolinium. The reduced availability of free gadolinium would result in an increased 
concentration of free protein in the measured sample and thus a longer relaxation time (lower 
relaxivity). Because the significant change in relaxation times was not noted for high 
concentrations of ProCA-30 and ProCA-31, for this argument to be valid, the process for 
reducing the concentration of EDTA via dialysis prior to relaxivity experiments may not have 
been as efficient for ProCA-32 and ProCA-33. This is highly unlikely since identical expression 
and purification procedures were implemented for isolation of all members of Class ProCA-3 
agents. Still, to investigate whether ProCA-32 and ProCA-33 had significant amounts of excess 
chelator present in their stock samples relative to ProCA-31, a fluorescence titration with 
rhodamine-5N was completed by senior research David Xue. The instrumental conditions for 
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this experiment were identical to those listed in chapter 2 (section 2.5). Concentrations of 50µM 
ProCA-31 (control), ProCA-32, and ProCA-33 were each combined with 1µM of dye in 10mM 
Tris/HCl 100mM NaCl chelex pH 7.44. Increasing concentrations of gadolinium were titrated 
into the system (Figure 5.19).  
 
Figure 5.19. Determination of excess EDTA in contrast agent samples. (A) Fluorescence 
intensity spectrum of ProCA-31. (B) Fluorescence intensity spectrum of ProCA-32. (C) 
Fluorescence intensity spectrum of ProCA-33. Sample conditions: 1µM rhodamine-5N, 50µM 
protein in 10mM Tris 100mM NaCl chelex pH 7.44. 
 
Assuming that the binding of the tested agents to gadolinium is 1 to 2, the fluorescence 
intensity above 100µM added gadolinium (1 to 2 ratio) should not increase if excess EDTA is 
present. Here, EDTA would compete with rhodamine-5N for binding gadolinium. However, this 
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effect is not observed. Above 50µM of added gadolinium, the fluorescence intensity sharply 
increases for all tested contrast agents, allowing excess free gadolinium to bind to rhodamine-5N 
(Figure 5.20). Due to the lack of points collected between 50µM and 100µM added gadolinium, 
one cannot determine the whether the sharp increase exclusively occurs above 50µM added 
gadolinium. This would provide further insight into the binding mode of the tested agents. 
Nevertheless, this data indicates that not only is there very little free EDTA present in the protein 
stock samples, but the concentration of this chelator does not vary from protein to protein. 
Therefore, this phenomenon cannot be used to explain the lowered relaxivity. Additionally, 
while this fluorescence titration method has the potential to offer insight into the lowered 
relaxivity of ProCA-32 and ProCA-33, it does not effectively address the significant increase in 
relaxation times at higher concentrations of protein. Thus, it is more likely that the effect seen for 
ProCA-32 and ProCA-33 lowered relaxivities is due to dimerization or the heterogeneous nature 
of the gadolinium metal binding sites for the reasons previously outlined in this chapter. 
 
Figure 5.20. Effects of increasing concentrations of gadolinium on fluorescence intensity. 
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While dimerization effects may present a possible explanation for the significant increase 
in relaxation times for ProCA-33 in Figure 5.17, it is important to note the sharp increase in 
relaxation times above 38µM protein compared to the attenuated increase in that of ProCA-32 in 
Figure 5.15. If the effects seen were due to dimerization effects, the slope of increasing 
relaxation times for both ProCA-32 and ProCA-33 should be nearly identical. Though each 
variant maintains an aspartate mutation at different positions within the CD site, one would not 
expect that this positioning would significantly affect the relative dimerization potential of each 
agent. Thus, the heterogeneity of the metal binding sites presents a more plausible explanation 
for this phenomena observed in both ProCA-32 and ProCA-33. The glutamate to aspartic acid 
mutation made at position 60 is identical to the glutamate to aspartic acid mutation made at 
position 59 of Michael Henzl’s studies of rat α- and β-parvalbumins (Henzl’s numbering of 
parvalbumin residues counts the first methionine cleaved as residue number one whereas our 
studies do not) [34]. These studies report that the macroscopic association constants for calcium 
binding of the ProCA-33 mutation are as follows: K1 (M-1) is 1.2 (0.1) x 108 and K2 (M-1) is 7.8 
(0.3) x 106 [34]. Here, we assume that the CD site is the weaker gadolinium affinity site 
compared to that of the EF site in the E60D mutant (ProCA-33) compared to the wildtype 
association constants of α-parvalbumin (ProCA-30) in Henzl’s paper [34]. Assuming that the 
nature of calcium and gadolinium binding are similar for the reasons previously stated, it appears 
that ProCA-33 has a lower overall metal binding affinity (Figure 4.21). Still, the increased 
binding affinity differentiation between the CD and EF sites is enhanced in ProCA-33 compared 
to ProCA-32, as there is nearly a 100-fold differentiation between the association constants of 
ProCA-33 compared to the 10-fold difference in the ProCA-32 constants [34]. Therefore, a more 
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drastic increase in relaxation times is noted above 38µM protein (Figure 5.17). Theoretically, 
this increase should occur above 50µM protein. However, it’s possible that there is an error in 
estimation of the protein concentration due to the inconsistencies in the reported molar extinction 
coefficient for this variant. At concentrations of approximately 38-50µM and below, the 
relaxivity signal is predominantly due to saturation of both the weak (lower affinity CD site) and 
strong (higher affinity EF site) metal binding sites, as the protein concentration is significantly 
lower than that of the fixed gadolinium concentration of 100. The slope of this portion of the 
curve yields the average relaxivity of ProCA-33 and excess free gadolinium. Above 38-50µM 
protein, the introduction of excess protein or unoccupied metal binding sites “recruits” 
gadolinium ions to the stronger metal binding site, leaving the weaker metal binding sites 
unoccupied. Therefore, the increasing concentration of protein reduces the concentration of total 
saturated metal binding sites and relaxivity decreases. The slope of the curve above 38-50µM 
ProCA-33 corresponds to the relaxivity of the strong metal binding sites.    
5.5. Summary 
 Overall, both the traditional method of measurement and the fixed gadolinium 
experiments yield comparable relaxivity values, with the exception of ProCA-32. ProCA-32 and 
ProCA-33 maintain notably lower relaxivities compared to ProCA-30 and ProCA-31 members 
which do not bear a CD site mutation. This is primarily due to the significant increase in 
relaxation times following the 1:2 ratio for ProCA-32 and the 1:3 ratio for ProCA-33. As 
previously explained, this is likely due to the heterogeneous nature of the metal-binding sites.   
It appears that all members of Class ProCA-3 bind gadolinium in a 1:2 ratio. ProCA-33 
appears to bind gadolinium in a 1:3 ratio by the fixed gadolinium method. However, a reverse 
titration of the fixed gadolinium method allows one to conclude that the binding is 1:2. There are 
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a number of plausible explanations provided as an explanation for the lowered relaxivities of 
ProCA-32 and ProCA-33 compared to that of ProCA-30 and ProCA-31. Initially, dimerization 
effects were assumed to be the cause for the drastic increase in relaxation times above the 1 to 2 
ratio in ProCA-32 (Figure 5.15) and 1 to 3 ratio in ProCA-33 (Figure 5.17) due to the 
introduction of additional charged residues in the CD site compared to that of ProCA-30 and 
ProCA-31. However, this assumption does not address the gradual increase in relaxation times 
for ProCA-32 versus the sharp increase for ProCA-33. A more plausible explanation for the 
sharp increase in relaxation times is due to the heterogeneous nature of the metal binding sites 
within class ProCA-3 agents. As noted by the fixed gadolinium curves in Figures 5.15 and 5.17, 
initially, gadolinium occupies the strong affinity site (low relaxivity) site and then occupies the 
weak affinity site (higher relaxivity). The 100-fold differentiation noted in ProCA-33 compared 
to the 10-fold differentiation in ProCA-32 explains why a more pronounced increase in 
relaxation times was noted for ProCA-33. At higher concentrations of protein, the fixed 
concentration of gadolinium preferentially binds the strong metal binding affinity sites, reducing 
the concentration of protein saturated and lowering the overall relaxivity measured. Thus, lower 
relaxivities using the fixed gadolinium-increasing protein concentration method are noted for 
ProCA-32 and ProCA-33. Our secondary structure results from circular dichroism in chapter 4 
do not reveal any significant structural changes in the native structure of this class of contrast 
agents due to the CD site mutations made in ProCA-32 and ProCA-33. To provide a more 
concrete explanation to explain lower than expected relaxivity phenomenon noted by traditional 
method calculations, further investigation is required.   
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6. FINAL CONCLUSIONS AND FUTURE WORK 
In summary, the current expression protocol used yields a high quantity of overexpressed 
parvalbumin and its variants according to SDS Page gel analysis. However, this conclusion is 
based on evidence of consistency in loading samples onto the gel and on the contingency that the 
dense band observed at 12 kDa is primarily due to the presence of the desired protein. Minor 
modifications can be made to the procedure by eliminating overnight growth for expression. 
Though differences in optical density indicate enhanced cellular growth, overnight incubation 
does not yield a significant difference in the amount of protein expressed compared to three to 
four hours after induction. 
Through the development of optimal streptomycin sulfate precipitation conditions and salt 
gradient modification of the program used for FPLC Q-column separation, significant 
improvements were made (from 31.70 mg to 109.12 mg for ProCA-30; from 37.50 mg to 76.16 
mg for ProCA-31; from 32.60 mg to 60.21 mg for ProCA-32) compared to the old protocol to 
yield a significantly higher quantity of ProCA-30, ProCA-31, and ProCA-32. The yield for 
ProCA-33 did not increase due to experimental error made during the washing of the Q-column 
prior to FPLC injection. Nevertheless, newly modified purification protocol not only allows for 
excellent abstraction of the protein from the cell pellet but is also yields a high concentration of 
protein absent from DNA or RNA as compared to previous purification results.  
In the absence of EGTA sample treatment, all of the discussed members of Class ProCA-3 
yield alpha-helical structures that are sustained in the presence and absence of salt in varying 
concentrations of magnesium, calcium, gadolinium, and terbium. A high salt environment does 
little to destabilize the secondary structure of the protein. Additionally, one can conclude that the 
introduction of mutations within the CD binding site does not significantly alter the secondary 
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structure of the native form of the protein. Furthermore, the results indicate that the secondary 
structure is maintained in the presence of gadolinium under high salt conditions. This is of grave 
importance, as it gives insight into the structural stability of the contrast agents. From the 
observed CD spectrum analyses, a random coil formation was noted for all variants in the 
presence of 5mM gadolinium and terbium in the presence of 5mM EGTA. The denaturation of 
the aforementioned proteins is primarily due to a significant decrease in pH due to EGTA 
binding gadolinium or terbium. 
The relaxivity values obtained for ProCA-30, ProCA-31, ProCA-32, and to lower degree 
ProCA-33 seem to be very promising for the future of contrast agents because their relaxivity 
values are significantly higher than that of many commercial contrast agents (Tables 5.1 and 
5.2). With the exception of ProCA-32 values, the relaxivity values calculated by the traditional 
method are nearly identical to those achieved using the fixed gadolinium increasing protein 
concentration experiments. Reasons behind this observed phenomenon is not well understood. 
Failure to achieve identical relaxivity values for ProCA-32 requires further investigation. From 
the fixed 100µM Gd3+-varied protein concentration relaxivity experiments, strong experimental 
evidence supports ProCA-30, ProCA-31, and ProCA-32 binding gadolinium in a 1:2 protein to 
metal ratio. Studies of ProCA-33 using a reverse titration of the aforementioned binding mode 
experiment also allow one to assume that the contrast agent binds two gadolinium ions. The 
lower relaxivity values and attenuated or sharp increase in relaxation times for the fixed 
gadolinium-varied protein concentration experiments for ProCA-32 and ProCA-33 are likely due 
to the heterogeneous nature of the metal binding sites. Dimerization effects or the presence of 
residual EDTA present in the sample from our purification process are less likely to explain the 
effects observed. Correlating the relaxivity data with the circular dichroism data, it appears that 
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the measured relaxivity values are not necessarily affected by metal-induced structural changes. 
Once again, ProCA-32 is the only member of Class ProCA-3 whose increase in relaxivity from 
the 1 to 1 to the 1 to 2 ratio under both salt conditions doesn’t correlate significant changes in the 
protein’s secondary structure. The remaining members yield positive correlations with the CD 
data between their consistent relaxivity values under both salt conditions at 1 to 1 and 1 to 2 
ratios.  
Future fluorescence experiments will allow one to quantify the experimental metal 
dissociation constant of the members of Class ProCA-3. Future relaxivity experiments will be 
devoted to metal competition experiments to determine at what concentration gadolinium can be 
competed out of the contrast agent binding sites by physiologically relevant metal ions such as 
calcium, magnesium, zinc, etc. 1D and NMR diffusion experiments will further characterize the 
nature of differentiation between the metal binding sites in class ProCA-3 agents. The results 
from these experiments will allow for further screening for an optimal variant that will function 
as a contrast agent for MRI diagnostics. 
Overall, the studies of this thesis have made a significant contribution to the development of 
Class ProCA-3 agents. Because animal experiments and clinical trials require large amounts of 
highly concentrated contrast agent of 5mM or higher be injected into an animal or patient for 
image-enhancement screening, the optimized purification protocol aids in achieving a pure, high 
quantity of contrast agent to be used. The structural stability studies provide insight into the 
metal stability of the contrast agents and more specifically into the stability of the agents when 
saturated with gadolinium. The higher relaxivity values measured for the contrast agents 
compared to commercial analogue Gd-DTPA implies that there is a higher dose efficiency 
associated with contrast agent performance, meaning less contrast agent will be required to 
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achieve heightened differential signal intensity in an MR image compared to that of the 
commercial agents. This is a highly desired result as a lower injection dosage reduces the 
potential for the toxic effects associated with the release of a high concentration of free 
gadolinium (nephrogenic systemic fibrosis). Combined with future gadolinium-binding studies, 
metal selectivity studies, serum stability observations, and in vivo observations of image-
enhancement, Class ProCA-3 agents have the potential to be developed as general and targeted 
agents, making significant strides in the efficacy of MRI.  
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